Document:

Exhibit 10.1

 

SETTLEMENT
and license AGREEMENT

 

This SETTLEMENT AND LICENSE
AGREEMENT (this “Agreement”) is made and entered into as of the date of the last signature required by this
Agreement (the “Effective Date”) by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized
and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 (“Enzo”)
and Defendant Agilent Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware,
having offices at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 (“Agilent”). Enzo and Agilent are individually
referred to herein as a “Party,” and collectively as the “Parties.”

 

WITNESSETH

 

WHEREAS, Enzo has alleged
that Agilent infringes U.S. Patent No. 7,064,197 (“the ‘197 patent”) in an action styled Enzo Life Sciences,
Inc. v. Agilent Technologies, Inc., No. 1:12-cv-434-LPS, pending in the United States District Court for the District of Delaware
(the “Litigation”); and

 

WHEREAS, Agilent denies all
liability in the Litigation; and

 

WHEREAS, Agilent has alleged
that it does not infringe the ‘197 patent, and further, that the ‘197 patent is invalid and unenforceable; and

 

WHEREAS, Enzo disputes Agilent’s
allegations of invalidity, unenforceability, and non-infringement; and

 

WHEREAS, the Parties now
desire to settle the Litigation and to provide and receive certain releases, licenses and covenants not to sue, all on the terms
and conditions set forth herein; and

 

WHEREAS, this Agreement reflects
a settlement and compromise between the parties under Federal Rule of Evidence 408 with respect to Enzo’s claims and Agilent’s
defenses in the Litigation, including without limitation on the disputed issues of patent validity, enforceability, and infringement;

 

NOW, THEREFORE, in consideration of the above
recitals and the mutual covenants hereinafter contained, the Parties agree as follows:

SECTION 1: DEFINITIONS

 

As used in this Agreement,
the following terms shall have the following meanings:

 

“Affiliate” means, with
respect to a Party, (1) any Person that, as of the Effective Date, is directly or indirectly controlling, controlled by, or under
common control with, such Party, and (2) all future wholly-owned subsidiaries of such Party that are created by the Party in the
ordinary course of business or as a result of an internal reorganization of the Party (e.g., not an

    	1

    	

    

acquisition of, acquisition by, or merger with
another Person) and only for so long as that entity is a wholly-owned subsidiary of such Party. For purposes of this Agreement,
“control” means the ability to control the direction of the management and operations of the subject Person, whether
through ownership, contract or otherwise. Control will be presumed where a Party has ownership of 50% or more of the outstanding
voting shares of the Person. Notwithstanding anything to the contrary herein, the following Persons are not, and cannot be considered,
Affiliates of Agilent for the purposes of this Agreement so long as any patent infringement litigation or royalty obligation concerning
the Licensed Enzo Patents (or U.S. Patent No. 4,943,523) remains pending between Enzo and that Person (or any Affiliate of that
Person): Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm
Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Life
Technologies Corporation (now part of Thermo Fisher Scientific, Inc.); Roche Molecular Systems, Inc. (part of Hoffmann-La Roche
AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La Roche
AG); Roche Diagnostics GMBH (part of Hoffmann-La Roche AG), and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or their
respective Affiliates.

 

“Licensed Agilent
Products” means any past, current and future products and services, product lines, devices, instruments, systems, assays,
components, kits, hardware, software, or any combination of the foregoing, for which the making, using, selling, offering for sale,
importing, exporting, or other transfer or disposal by Agilent or its Affiliates would, but for the license granted in this Agreement,
infringe a Valid Claim of the Licensed Enzo Patents.

 

“Licensed Enzo Patents”
means (i) U.S. Patent No. 7,064,197; (ii) any patents and patent applications claiming priority to or through, or sharing a common
priority claim with, the foregoing; (iii) any foreign counterparts of any patents and patent applications covered in subparts (i)
and (ii); and (iv) any re-issues, re-examinations, renewals, substitutes, claim amendments made in post-grant proceedings (including
IPR and PGR proceedings, oppositions, and limitation proceedings), renewals, extensions, validations, restorations, revivals, continuations,
continuations-in-part, continuing prosecution applications, divisionals, and national phase filings of any patents and patent applications
covered in subparts (i), (ii), and (iii).

 

“Person”
means an individual, trust, corporation, partnership, joint venture, limited liability company, association, unincorporated organization,
or other legal entity.

 

“Third Party”
means any Person or entity other than the Parties to this Agreement and their Affiliates.

 

“Covered Third Party
Accused Products” means Third Party products and services that include as an element thereof any Licensed Agilent Products.

 

“Valid Claim”
means a claim of an issued patent that has not expired or been finally held invalid or unenforceable by a court or administrative
body of competent jurisdiction from which no appeal can be or is taken.

    	2

    	

    

SECTION
2: LICENSE, RELEASES, AND COVENANTS

 

2.1 License. Subject to the terms and
conditions hereof, including Agilent’s timely payment of the Payment under Section 3.1, Enzo hereby grants to Agilent and
its Affiliates a fully paid-up non-exclusive, non-transferable (except as set forth in Section 5), worldwide license under the
Licensed Enzo Patents to make, have made, develop, have developed, use, import, export, distribute, sell, have sold, transfer or
otherwise dispose of, offer for sale, and practice all processes and methods in connection with, the Licensed Agilent Products.

 

Agilent shall not have the right to sublicense
or otherwise grant, in whole or in part, licenses under the Licensed Enzo Patents. The license granted herein shall not extend
to cover any products of a Third Party that acquires or is acquired by Agilent or its Affiliates (whether by merger, consolidation,
share acquisition, or acquisition of all or substantially all assets or otherwise), including without limitation for products made,
used, imported, exported, distributed, sold, offered for sale, developed, advertised, and practiced by such Third Party before
the date of such acquisition. The license granted herein shall not include any rights to the Licensed Enzo Patents other than those
expressly provided by this section. No license or immunity is granted under this Agreement by Enzo, either directly or by implication,
estoppel, or otherwise, to any Person acquiring Licensed Agilent Products for the modification or combination by such Person of
Licensed Agilent Products with other items other than (i) in the ordinary manner in the ordinary course of use of Licensed Agilent
Products, (ii) as specified in Sections 2.2 and 2.3, or (iii) as otherwise permitted by the law of patent exhaustion.

 

2.2 Enzo Release of Agilent.
Subject to the terms and conditions hereof, including Agilent’s timely payment of the Payment under Section 3.1, Enzo, on
behalf of itself and its Affiliates, releases, acquits and absolutely and forever discharges Agilent and its Affiliates, and each
of their officers, directors, shareholders (other than Persons, including Restricted Entities as defined in paragraph 5.3 below,
that may have liability for patent infringement unrelated to their status as shareholders of Agilent), managers, employees, agents,
and attorneys (“Agilent Released Persons”) from any claim, counterclaim, demand, allegation, damage, loss, debt, liability,
account, reckoning, indemnity, obligation, cost, expense, lien, attorneys’ fee, any other action or cause of action of any
kind or nature, whether now known or unknown, suspected or unsuspected, matured or unmatured, asserted or unasserted, in law or
equity, for (i) infringement of the Licensed Enzo Patents to the extent related to the business of Agilent and occurring before
the Effective Date; (ii) the claims and defenses asserted by and against Enzo and Agilent in, and the conduct of, the Litigation;
and (iii) the conduct of settlement negotiations (except for representations or obligations expressly included in this Agreement).

 

Enzo also provides a limited
release to customers, distributors, resellers, and users of any Licensed Agilent Products for any claim, based on conduct occurring
before the Effective Date, of infringement of the Licensed Enzo Patents by Licensed Agilent Products and Covered Third Party Accused
Products but only to the extent that Agilent’s own conduct with respect to such customer, distributor, reseller, or user
infringement would give rise to a colorable claim against Agilent for direct or indirect infringement under 35 U.S.C. § 271
(and/or a claim based on the same types of indirect infringement theories asserted against Agilent in the Litigation), or other
law of patent infringement outside the United States as may be applicable, but for the licenses,

    	3

    	

    

releases, and covenants granted
to Agilent herein. For the avoidance of doubt, to the extent any customers, distributors, resellers, or users of any Licensed Agilent
Product infringe the Licensed Enzo Patents for any reason that would not also give rise to a colorable claim against Agilent for
direct or indirect infringement under 35 U.S.C. § 271 (and/or a claim based on the same types of indirect infringement theories
asserted against Agilent in the Litigation), or other law of patent infringement outside the United States as may be applicable,
but for the licenses, releases, and covenants granted to Agilent herein, such infringement is not released hereunder.

 

The scope of this release is fixed as of the
Effective Date. Except as expressly set forth herein, this release shall not apply to any Person, including without limitation
any Third Party, or any business, assets, or products thereof, acquired by Agilent or its Affiliates (whether by merger, consolidation,
share acquisition, or acquisition of all or substantially all assets or otherwise) after the Effective Date.

 

Enzo irrevocably waives all rights arising
under California Civil Code Section 1542 (and any similar or analogous requirement of law) with respect to the foregoing releases,
to the extent Section 1542 otherwise would apply. Enzo acknowledges and understand that Section 1542 provides that:

 

A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by
him must have materially affected his settlement with debtor.

 

2.3 Limited Enzo Covenant
Not To Sue. Subject to the terms and conditions hereof, including Agilent’s timely payment of the Payment under Section
3.1, Enzo, on behalf of itself and its Affiliates, covenants during the term of this Agreement not to sue (1) Agilent or its Affiliates
for infringement of the Licensed Enzo Patents; or (2) Agilent’s distributors, resellers, customers, and users for (i) infringement
of the Licensed Enzo Patents by a Licensed Agilent Product, or (ii) infringement of the Licensed Enzo Patents by a Covered Third
Party Accused Product using or containing a Licensed Agilent Product, but only to the extent that Agilent’s own conduct with
respect to such customer, distributor, reseller, or user infringement would give rise to a colorable claim against Agilent for
direct or indirect infringement under 35 U.S.C. § 271 (and/or a claim based on the same types of indirect infringement theories
asserted against Agilent in the Litigation), or other law of patent infringement outside the United States as may be applicable,
but for the licenses, releases, and covenants granted to Agilent herein. For the avoidance of doubt, to the extent any customers,
distributors, resellers, or users of any Licensed Agilent Product infringe the Licensed Enzo Patents for any reason that would
not also give rise to a colorable claim against Agilent for direct or indirect infringement under 35 U.S.C. § 271 (and/or
a claim based on the same types of indirect infringement theories asserted against Agilent in the Litigation), or other law of
patent infringement outside the United States as may be applicable, but for the licenses, releases, and covenants granted to Agilent
herein, this covenant does not apply. This covenant not to sue is non-assignable by Agilent or by any of Agilent’s distributors,
resellers, customers, and users who benefit from this covenant not to sue.

    	4

    	

    

2.4 Agilent Release of
Enzo. Agilent, on behalf of itself and its Affiliates, releases, acquits and absolutely and forever discharges Enzo and its
Affiliates, and each of their officers, directors, shareholders, managers, employees, agents, and attorneys from any claim, counterclaim,
demand, allegation, damage, loss, debt, liability, account, reckoning, indemnity, obligation, cost, expense, lien, attorneys’
fee, any other action or cause of action of any kind or nature, whether now known or unknown, suspected or unsuspected, matured
or unmatured, asserted or unasserted, in law or equity, arising out of or related to: (i) infringement of the Licensed Enzo Patents
to the extent occurring before the Effective Date; (ii) the claims and defenses asserted in, and the conduct of, the Litigation;
and (iii) the conduct of settlement negotiations (except for representations or obligations expressly included in this Agreement).

 

Agilent irrevocably waives all rights arising
under California Civil Code Section 1542 (and any similar or analogous requirement of law) with respect to the foregoing releases,
to the extent Section 1542 otherwise would apply. Agilent acknowledges and understand that Section 1542 provides that:

 

A general release does not extend to
claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by
him must have materially affected his settlement with debtor.

 

2.5 Covenant Not to Challenge.
After the Effective Date and for so long as Agilent’s license is in force, Agilent further covenants that, except as (1)
required by law or (2) in defense of an action for infringing a Licensed Enzo Patent brought against it or its Affiliates, or against
its or their agents, representatives, suppliers, vendors, contractors, manufacturers, distributors, licensees, resellers, licensees,
users, and customers (direct or indirect) involving any Licensed Agilent Products, it shall not knowingly and voluntarily contest
(or assist in the contest) in any forum, including Federal Courts, whether under 28 U.S.C. §§ 2201-2202 or not, the United
States Patent and Trademark Office, and/or the International Trade Commission, that the Licensed Enzo Patents are valid and enforceable;
provided, however, nothing in this Agreement shall prevent Agilent or its Affiliates from complying with or responding to any court
or governmental order or subpoena relating to the Licensed Enzo Patents. Notwithstanding the foregoing, nothing in this Agreement
will preclude Agilent and its Affiliates from making any disclosure, providing information or producing documents as required by
law, court order or legal process (including, without limitation, litigation related to discovery and/or subpoena), even if made
in connection with a proceeding challenging the validity or enforceability of one or more of the Licensed Enzo Patents, and any
such disclosure will not be considered a breach of this Agreement. It is understood that Agilent’s and its Affiliates’
providing factual statements regarding Licensed Agilent Products or any Third Party products containing them in response to a validly
propounded subpoena will not be considered as assisting in the contest as used above. Agilent reserves the right to raise any and
all defenses and counterclaims, including, but not limited to, invalidity and unenforceability of the Licensed Enzo Patents, and
to otherwise contest the validity and enforceability of the Licensed Enzo Patents in any forum, that it could have raised in the
Litigation, if a Licensed Enzo Patent is asserted based on Licensed Agilent Products or Third Party products containing them against
Agilent, its Affiliates, customers, licensees,

    	5

    	

    

partners or users after the
Effective Date; and Enzo reserves the right to raise any and all claims and defenses in opposition.

 

2.6 Limited Standstill.
Each Party agrees that it shall not, and that it shall cause each of its Affiliates or representatives not to, file or otherwise
bring any action or lawsuit alleging patent infringement against the other Party for a period of three (3) years after the Effective
Date of this Agreement or until the termination of this Agreement, whichever is earlier (“Standstill Period”). Nothing
in this Section 2.6 shall enlarge or otherwise modify the licenses, releases, or covenants set out in this Agreement. The foregoing
provision is personal to the Parties, is non-assignable (except as set forth in Section 5.2), and does not apply to any other Person.
Further, it shall not prevent either Party from engaging in discussions with the other Party or any other Person regarding the
licensing of its patents or from enforcing its patents against any Person other than a Party. During this Standstill Period, any
patent infringement claim that one Party has against the other shall be tolled and any damages will accrue and be recoverable to
the full extent permitted by 35 U.S.C. § 286. For clarity, nothing shall prevent the Parties from seeking damages after the
Standstill Period terminates for patent infringement occurring during the Standstill. If either Party violates this Standstill
agreement, the other Party shall be free to immediately end the Standstill Period. If a complaint for patent infringement is filed
after expiration of the Standstill Period, no Party may rely on the Standstill Period as a basis for any claim, counterclaim, or
defense, including without limitation an assertion of laches or to defend against an injunction. Notwithstanding the foregoing,
a Party still may assert any claim, counterclaim, or defense available, including without limitation an assertion of laches or
a defense against an injunction, to the extent it does not specifically rely on the Standstill Period as a basis. For the avoidance
of doubt, nothing in this provision or any other provision of this Agreement shall prevent either Party from intervening in patent
litigation between the other Party and a Third Party based on any indemnity or other contractual obligation that either Party owes
to such Third Party.

 

2.7 Acquisitions. The licenses, releases, and covenants set
forth above shall exclude any products of another Person that is acquired (whether by merger, consolidation, share acquisition,
or acquisition of all or substantially all assets or otherwise) by Agilent or its Affiliates on or after the Effective Date. The
standstill set forth above shall not apply to any action or lawsuit in which the acquired Person is a party and that is pending
as of the date of the acquisition of the acquired Person.

 

2.8 Modifications and
Combinations In Manner Other Than Ordinary Course. No license or immunity is granted under this Agreement by Enzo, either directly
or by implication, estoppel, or otherwise, to any Person acquiring Licensed Agilent Products for the modification or combination
by such Person of Licensed Agilent Products with other items other than in the ordinary manner in the ordinary course of use of
Licensed Agilent Products, or as specified by Sections 2.2 and 2.3, or as otherwise permitted by the law of patent exhaustion.

 

2.9 No Extinguishment Of Other Outstanding Royalty Obligations.
For the avoidance of doubt, nothing in this Agreement shall operate to extinguish the obligation of any Person to pay royalties
to Enzo arising from an obligation outside of this Agreement (including via contract, operation of law, judicial ruling, or otherwise).

    	6

    	

    

2.10 No Other Rights.
No rights or covenants are granted under any patents except as expressly provided herein, whether by implication, estoppel or otherwise.
No right to grant covenants, rights, sublicenses, or to become a foundry for Third Parties is granted under this Agreement. The
Parties agree that, except as expressly set forth herein, the licenses, releases and covenants set forth in this Agreement (including
Section 2) expressly exclude any methods, systems, products, services and/or components of any Third Party. The Parties further
agree that, except as expressly provided herein, this Agreement does not cut off Enzo’s rights to enjoin, control or extract
royalties with respect to such Third Party’s methods, systems, products, services and/or components.

 

SECTION
3: MONETARY CONSIDERATION

 

3.1 Payment. As partial
consideration for this Agreement and the dismissal by Enzo of the Litigation hereunder, Agilent agrees to pay to Enzo a total of
nine million U.S. Dollars ($9,000,000.00) (“Payment”), payable by Agilent to Enzo no later than seven (7) business
days following the Effective Date of this Agreement in lawful money of the United States, in immediately available funds, by wire
transfer to the following account: # # #

 

3.2 Taxes / Costs.
Each Party acknowledges that this Agreement may have U.S. federal and state tax (collectively, “Tax”) or other consequences,
and that the Party is not relying on any other Party for advice, representations or communications as to any potential Tax or other
consequences. This Agreement is enforceable regardless of its Tax or other consequences. The Parties agree that they shall bear
their own costs and attorneys’ fees relating to or arising from the Litigation and to the documentation and negotiation of
this Agreement.

 

3.3 Dismissal. Within
three (3) court days after the Payment of the consideration to Enzo under this Section 3 has cleared, the Parties shall cause their
respective counsel to execute and file the stipulated motion in the form set forth in Exhibit A dismissing with prejudice
all of Enzo’s claims against Agilent in the Litigation. The Parties shall promptly proceed with any and all additional procedures
needed to dismiss the Litigation as set forth above, with each Party to bear its own costs and attorneys’ fees. The Parties
also agree to submit to the court appropriate stipulations and proposed orders for extensions of time for all due dates in the
Litigation so that neither Party is required to incur unnecessary expenses in the Litigation between the Effective Date and the
date the Litigation is dismissed. The Parties acknowledge and agree that this Agreement is enforceable according to its terms with
respect to final dismissal with prejudice of all claims and counterclaims in the Litigation.

 

3.4 No Admission of Liability. This
Agreement is the result of a compromise and will not at any time be considered as an admission of liability or responsibility,
or lack thereof, on the part of Enzo or Agilent. By entering into this Agreement, neither Agilent nor any of its Affiliates is
conceding that it acted wrongfully in any fashion whatsoever. Except under this Agreement as expressly set forth in Section 3.1,
Agilent and its Affiliates expressly deny that they are liable to Enzo in any way.

 

3.5 Full Settlement.
The Parties agree that this Agreement is in full and complete settlement of the rights and obligations of the Parties in connection
with the Litigation. This Agreement may

    	7

    	

    

be pleaded as a defense to
any action, suit or claim and may be used as a basis for an injunction against any such action, suit, claim, or other proceeding
of any type which may be prosecuted, initiated or attempted in violation of the terms hereof. A Party is entitled to recover from
the other adverse party reasonable attorneys’ fees and other related legal expenses incurred in defending against any suit,
action or claim brought or attempted by the other party in violation of the terms of this Agreement.

 

Section 4: TERM AND termination

 

4.1 Term. The term of this Agreement
shall commence upon the Effective Date and shall continue until the expiration of the enforceability period of the last to expire
of the Licensed Enzo Patents, unless earlier terminated as set forth in Section 4.2 below.

 

4.2 Termination. If
Agilent fails to make the payment set forth in Section 3.1 in the time frame required by Section 3.1, then Enzo may terminate this
Agreement immediately upon further written notice to that effect and the license, releases, covenants, and standstill granted by
Section 2 of this Agreement shall immediately terminate, be deemed null and void ab initio, and be of no force and effect.

 

SECTION
5: ASSIGNMENT

 

5.1 Assignment. The license and other rights granted by Enzo
in this Agreement are personal to Agilent. Except as otherwise permitted in this Section, Agilent may not assign, delegate, or
otherwise transfer this Agreement or any license or rights hereunder without the prior written consent of Enzo. The limitations
on assignment set forth in Section 5 do not apply to an internal reorganization of a Party or its Affiliates (re-incorporation
or the like). Any other purported assignment, delegation, or transfer without the prior written consent of Enzo will be null and
void ab initio and without effect. Except as set forth in Sections 2.1, 2.2, and 2.3 hereof, nothing herein expressed or
implied will give or be construed to give any Person who is not a Party any legal or equitable rights hereunder.

 

5.2 Permitted Assignment
by Agilent. Notwithstanding the provisions of Section 5.1, Agilent may assign its rights under this Agreement, in whole or
in part, without Enzo’s prior written or oral consent, to a Person with whom Agilent is merged or consolidated, or who acquires
all or substantially all of Agilent’s business subject to the Litigation; provided however, that (1) this Agreement shall
not be assigned to multiple Persons; (2) any such assignment of rights will not extend to (a) products or services of such Person
that pre-existed the merger, consolidation or acquisition (or natural evolutions or extensions thereafter), or (b) products or
services that are subsequently developed by operating entities of the Person distinct from the Agilent business so acquired; (3)
any such assignment of rights shall not relieve such Person from any obligations that such Person may have under this Agreement
as a result of the merger, consolidation, or acquisition or the assignment of rights by Agilent; (4) the standstill provided in
Section 2.6 shall apply only to patents owned or controlled by Agilent prior to the merger, consolidation, or acquisition; (5)
the covenant not to challenge provided in Section 2.5 shall not apply to any challenge by such Person that was pending prior to
the merger, consolidation, or acquisition or

    	8

    	

    

that is commenced in response
to or in connection with a suit or threat of suit by Enzo for infringement of a Licensed Enzo Patent; and (6) Agilent obtains from
such Person a written agreement to be bound by the terms and conditions of this Agreement (as modified by this section) and furnishes
the same to Enzo.

 

In the event that Agilent
does not continue to exist as a distinct operating entity (such as a wholly-owned subsidiary) after the transaction, the rights
of Agilent hereunder so assigned only extend to Licensed Agilent Products existing as of the date of the transaction and natural
evolutions of Licensed Agilent Products created after the date of the transaction, and will not otherwise extend to any products,
services, or activities of the acquiring Person prior to, on or after the date of the transaction. Furthermore, in the event that
Agilent does not continue to exist as a distinct operating entity (such as a wholly-owned subsidiary) after the transaction, the
releases and covenants provided by Agilent and its Affiliates shall run with the rights being assigned or transferred and shall
be binding on any permitted successors-in-interest, transferees, or assigns thereof, except that (i) the standstill provided in
Section 2.6 shall apply only to patents owned or controlled by Agilent prior to the merger, consolidation, or acquisition; and
(ii) the covenant not to challenge provided in Section 2.5 shall not apply to any challenge by such successor-in-interest, transferee,
or assign that was pending prior to the merger, consolidation, or acquisition or that is commenced in response to or in connection
with a suit or threat of suit by Enzo for infringement of a Licensed Enzo Patent. For avoidance of doubt, any such assignment of
rights will not extend to any Third Party products or services existing prior to the time of transaction or natural evolutions
or extensions thereof. Any purported assignment, delegation, or transfer under this Section 5.2 that does not comply with the foregoing
will be null and void ab initio and without effect.

 

5.3 Further Restriction
on Assignment by Agilent: Notwithstanding the provisions of Sections 5.1 and 5.2, in no event may this Agreement, including
the license and rights granted hereunder, be assigned, delegated, or otherwise transferred without Enzo’s prior written consent
to any of the following: Abbott Laboratories; Abbot Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics,
Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina,
Inc.; Life Technologies Corporation (now part of Thermo Fisher Scientific, Inc.); Roche Molecular Systems, Inc. (part of Hoffmann-La
Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La
Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or any of the respective Affiliates of any of the foregoing
(each a “Restricted Entity”), so long as any patent infringement litigation concerning any of the Licensed Enzo Patents
remains pending between Enzo and the respective aforementioned Restricted Entities.

 

5.4 Stock Purchase and
Similar Transactions. For the avoidance of doubt, a Third Party’s (including a Person with whom Agilent is merged or
consolidated, a Person who acquires all or substantially all of Agilent’s business subject to the Litigation, and any Restricted
Entity) acquisition of Agilent by stock purchase, reverse triangular merger, or similar transaction does not constitute an assignment
of the Agreement by Agilent where Agilent (or its successor entity) continues to exist as a distinct operating entity (for example,
as a wholly-owned subsidiary of the Person or Restricted Entity) after the date of the acquisition, provided that the licenses,

    	9

    	

    

covenants, and releases granted
herein shall not extend to (a) products or services of such Person or Restricted Entity that pre-existed the merger, consolidation
or acquisition (or natural evolutions or extensions thereafter), or (b) products or services that are subsequently developed by
operating entities of the Person distinct from the Agilent business so acquired.

 

5.5 Permitted Assignment
by Enzo. All license rights, releases, and covenants, and other obligations contained herein shall run with the Licensed Enzo
Patents, as it applies to the license rights and covenants contained in Sections 2.1 through 2.6, inclusive, and shall be binding
on any successors-in-interest or assigns thereof. For the avoidance of doubt, any assignment of a Licensed Enzo Patent to any other
Person shall be subject to this Agreement.

 

SECTION
6: MISCELLANEOUS PROVISIONS

 

6.1 Representations:

 

6.1.1 Enzo Representations:
Enzo represents and warrants that: (i) as of the Effective Date, Enzo and/or its Affiliates own the Licensed Enzo Patents, (ii)
Enzo has the right (or the ability to require its Affiliates, as may be applicable) to grant the license, releases, and covenants
with respect to the Licensed Enzo Patents and the standstill set forth herein; (iii) as of the Effective Date, it has not assigned
or otherwise transferred to any other Person any rights to the Licensed Enzo Patents that would prevent Enzo from conveying the
rights set forth herein; and (iv) the person executing this Agreement on behalf of Enzo has the full right and authority to enter
into this Agreement on Enzo’s behalf.

 

6.1.2 Agilent Representations:
Agilent represents and warrants that: (i) as of the Effective Date, Agilent has the right to grant the releases and covenants set
forth herein; and (ii) the person executing this Agreement on behalf of Agilent has the full right and authority to enter into
this Agreement on Agilent’s behalf.

 

6.1.3 Disclaimer of Representation.
Nothing in this Agreement shall be construed as (i) a representation or warranty by Enzo as to the scope, validity, or enforceability
of any patent; (ii) a representation or warranty that the manufacture, use, or sale of any products will not utilize or infringe
any intellectual property rights; and (iii) any obligation by Enzo to pay annuities or otherwise maintain any patents in force
in any country.

 

6.2 Confidentiality.
From and after the Effective Date, neither Party shall disclose the existence or terms of this Agreement except:

 

6.2.1 with the prior written
consent of the other Party;

 

6.2.2 to any governmental
body having jurisdiction and specifically requiring such disclosure;

 

6.2.3 in response to a valid
document request or subpoena or as otherwise may be required by law, legal process or order of a court, provided a protective order
is in place that limits disclosure of such information to outside counsel only and the disclosing Party provides

    	10

    	

    

the other Party with written
notice at least ten (10) business days prior to disclosure to permit the other Party the opportunity to object and/or to seek a
court-entered protective order or comparable court-ordered restriction, and shall reasonably cooperate with the other Party in
its efforts to obtain that protective order and take all other reasonable actions in an effort to minimize the nature and extent
of such disclosure and obtain confidential treatment to the extent available;

 

6.2.4 for the purposes
of disclosure in connection with the Securities and Exchange Act of 1934, as amended, the Securities Act of 1933, as amended,
and any other reports filed with the Securities and Exchange Commission (expressly including, but not limited to, Form 8K disclosures),
or any other filings, reports or disclosures that may be required under applicable laws or regulations;

 

6.2.5 to a Party’s
accountants, legal counsel, tax advisors and other financial and legal advisors and other professional advisors in their capacity
of advising the party in such matters, subject to obligations of confidentiality and/or privilege at least as stringent as those
contained herein;

 

6.2.6 with obligations of
confidentiality at least as stringent as those contained herein, to a counterparty in connection with a proposed merger, acquisition,
financing or similar transaction.

 

6.2.7in connection with
tax audits or to fulfill its corporate financial reporting obligations under GAAP;

 

6.2.8with obligations
of confidentiality at least as stringent as those contained herein, by any Party and its Affiliates as required to enforce this
Agreement or establish rights hereunder;

 

6.2.9 to officers, key
shareholders and/or employees with a need to know, attorneys, accountants and directors, who are under obligations of confidentiality
(which may include professional responsibility obligations) at least as stringent as those contained herein; and

 

6.2.10to its Affiliates,
who are similarly bound by this Agreement or under obligations of confidentiality at least as stringent as those contained herein.

 

6.2.11 to Third Parties
who make, develop, sell, offer to sell, export, import, distribute, resell, or otherwise dispose of any Licensed Agilent Product
or who make, develop, sell, offer to sell, export, import, distribute, resell, or otherwise dispose of any Covered Third Party
Accused Product, and who have a need to know, under obligations of confidentiality at least as stringent as those contained herein.

 

Notwithstanding anything else in this Agreement
to the contrary, a Party may also disclose to anyone any information that is publicly available, through no breach by any Party
of the confidentiality obligations hereunder.

    	11

    	

    

6.3 Notices. All notices
required or permitted to be given hereunder shall be in writing and shall be delivered by hand, or, if dispatched by prepaid air
courier, with package tracing capabilities or by registered or certified airmail, postage prepaid, addressed as follows:

 

If to Enzo:

 

Dr. Elazar Rabbani

Enzo Life Sciences, Inc.

527 Madison Avenue

New York, NY 10022

 

Copy to (which does not constitute notice):

 

Michael Stadnick

Desmarais LLP

230 Park Avenue

New York, NY 10169

 

If to Agilent:

 

Office of the General Counsel/Chief Legal Officer

Agilent Technologies, Inc.

5301 Stevens Creek Boulevard

Santa Clara, CA 95051

 

Copy to (which does not constitute notice):

 

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

1201 North Market Street, 16th Floor

P.O. Box 1347

Wilmington, DE 19899-1347

 

Such notices shall be deemed
to have been served when received by addressee. Either Party may give written notice of a change of address and, after notice of
such change has been received, any notice or request shall thereafter be given to such Party as above provided at such changed
address.

 

6.4 Publicity. Neither
Party will issue a press release or any other public announcement regarding this Agreement or the settlement of the Litigation
unless the other Party provides prior consent in writing. Notwithstanding the foregoing and Section 6.2 above, upon inquiry either
Party may state that Enzo and Agilent have entered into a settlement agreement.

    	12

    	

    

6.5 Governing Law / Jurisdiction.
This Agreement and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all
respects in accordance with the laws of the United States of America and the State of Delaware, without reference to conflict of
laws principles. Enzo and Agilent agree (a) that all disputes and litigation regarding this Agreement, its construction and matters
connected with its performance be subject to the exclusive jurisdiction of the state and federal courts in the District of Delaware
(the “Court”), and (b) to submit any disputes, matters of interpretation, or enforcement actions arising with
respect to the subject matter of this Agreement exclusively to the Court. The Parties hereby waive any challenge to the jurisdiction
or venue of the Court over these matters.

 

6.6 Sophisticated Parties
Represented by Counsel. The Parties each warrant and represent that (i) they are sophisticated parties represented at all relevant
times during the negotiation and execution of this Agreement by counsel of their choice, and that they have executed this Agreement
with the consent and on the advice of such independent legal counsel; (ii) they and their counsel have determined through independent
investigation and robust, arm’s-length negotiation that the terms of this Agreement shall exclusively embody and govern the
subject matter of this Agreement, (iii) it investigated the facts pertinent to this Agreement as it deemed necessary, (iv) no other
Person or Party, nor any agent or attorney of a Party, made any promise, representation or warranty whatsoever, express or implied,
not contained in this Agreement concerning the subject matter of this Agreement to induce it to execute this Agreement, (v) it
has not executed this Agreement in reliance on any promise, representation or warranty whatsoever, express or implied, not contained
in this Agreement concerning the subject matter of this Agreement, and (vi) it has not executed this Agreement in reliance on any
promise, representation or warranty not contained herein. The Parties included this paragraph to preclude any claim that any Party
was fraudulently induced to execute this Agreement and to preclude the introduction of parol evidence to vary, interpret, supplement
or contradict the terms of this Agreement.

 

6.7 Bankruptcy. The Parties acknowledge and agree that all
rights and licenses granted by Enzo under or pursuant to this Agreement are, and will otherwise be deemed to be, for purposes of
Section 365(n) of the United States Bankruptcy Code, as amended (the “Bankruptcy Code”), licenses of rights to “intellectual
property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that, notwithstanding anything else in this
Agreement, Agilent and its Affiliates, as the licensee of such intellectual property rights under this Agreement, will retain and
may fully exercise all of its rights and elections under the Bankruptcy Code (including, without limitation, a Agilent and its
Affiliates’ right to the continued enjoyment of the rights and licenses granted by Enzo under this Agreement). Notwithstanding
the foregoing, this Agreement shall be deemed and treated as an executory contract under Section 365 of the Bankruptcy Code and
is subject to the restrictions on assumption and assignment in section 365(c). Further, this provision shall not alleviate or contravene
the restrictions on assignments and acquisitions set forth in this Agreement.

 

6.8 No Laundering. The Parties understand and acknowledge
that the licenses, releases, and covenants granted to Agilent and its Affiliates by Enzo hereunder are intended to cover only the
bona fide products or services of Agilent and its Affiliates and are not intended to cover patent laundering activities (i.e.,
activities that are undertaken solely for the purpose of improperly

    	13

    	

    

extending licensed rights to cover any activity of any third party
acting outside the scope of Agilent’s or its Affiliates’ licensed activities). The Parties further agree that a purchase
of a product from a supplier and resale of such product in substantially the same form back to the same suppler is not licensed
under this Agreement. Nothing in this Agreement shall be construed to license sham sales or sham service contracts executed by
Agilent or any of its Affiliates with any third party solely for the purpose of improperly extending licensed rights to cover any
activity of any third party acting outside the scope of Agilent’s (or its Affiliates’) licensed activities.

 

6.9 Severability.
If any provision of this Agreement is held to be illegal or unenforceable, such provision shall be limited or eliminated to the
minimum extent necessary so that the remainder of this Agreement will continue in full force and effect and be enforceable. The
Parties agree to negotiate in good faith an enforceable substitute provision for any invalid or unenforceable provision that most
nearly achieves the intent of such provision.

 

6.10 Entire Agreement.
The Parties hereby agree that (i) this is an enforceable agreement; (ii) this Agreement constitutes the entire and only understanding
of each of them with respect to the subject matter of the Agreement, and merges, supersedes and cancels all previous agreements
and understandings, whether oral or written, with respect to the subject matter of the Agreement; (iii) no oral explanation or
oral information by any Party hereto shall alter the meaning or interpretation of this Agreement; (iv) the terms and conditions
of this Agreement may be altered, modified, changed or amended only by a written agreement that identifies itself as an amendment
to this Agreement and is executed by duly authorized representatives of Enzo and Agilent; (v) the language of this Agreement has
been approved by counsel for each of them, and shall be construed as a whole according to its fair meaning; and (vi) none of the
them (nor their respective counsel) shall be deemed to be the draftsman of this Agreement in any action which may hereafter arise
with respect to the Agreement.

 

6.11 Modification; Waiver.
No modification or amendment to this Agreement, nor any waiver of any rights, will be effective unless assented to in writing by
the Party to be charged, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any
subsequent breach or default.

 

6.12 Construction; Language.
Any rule of construction to the effect that ambiguities are to be resolved against the drafting Party will not be applied in the
construction or interpretation of this Agreement. As used in this Agreement, the words “include” and “including”
and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without
limitation.” The headings in this Agreement will not be referred to in connection with the construction or interpretation
of this Agreement. This Agreement is in the English language only, which language shall be controlling in all respects, and all
notices under this Agreement shall be in the English language.

 

6.13 Counterparts.
This Agreement may be executed in counterparts or duplicate originals, both of which shall be regarded as one and the same instrument,
and which shall be the official and governing version in the interpretation of this Agreement. This Agreement may be executed by

    	14

    	

    

facsimile signatures or other
electronic means and such signatures shall be deemed to bind each Party as if they were original signatures.

 

IN WITNESS WHEREOF, the Parties hereto have caused
this Agreement to be signed below by their respective duly authorized officers.

 

Enzo Life Sciences, Inc.

 

	By:	 	/s/ Elazar Rabbani	 
	 	 	 	 
	Name:	 	Elazar Rabbani	 
	 	 	 	 
	Title:	 	Chairman and CEO	 
	 	 	 	 
	Date:	 	1/4/16	 

 

Agilent Technologies, Inc.

 

	By:	 	/s/ Jacob Thaysen	 

 

	Name: 	Jacob Thaysen	 
	 	 	 
	Title:	President, Diagnostics and Genomics Group, Agilent Technologies, Inc.	 

 

	Date:	 	1/4/16	 

    	15

    	

    

EXHIBIT A

STIPULATED MOTION FOR DISMISSAL OF LITIGATION

 

UNITED STATES DISTRICT COURT

OF DELAWARE

 

	
        ENZO LIFE SCIENCES, INC.

         

        vs.

         

        AGILENT TECHNOLOGIES, INC.

         

        Defendant.
	
        )

        )

        )

        )

        )

        )

        )

        )
	C.A. No. 12-434-LPS
	 	)	 

 

joint
Stipulation Of dismissal with prejudice

 

Pursuant to Rule 41(a)(1)(A)(ii)
of the Federal Rules of Civil Procedure, Plaintiff, Enzo Life Sciences, Inc., and Defendant Agilent Technologies, Inc., by and
through their respective counsel, hereby stipulate to the dismissal with prejudice of this action, including all claims and defenses.
Each party shall bear its own attorneys’ fees and costs.

 

	 	Respectfully submitted,
	 	 
	
        FARNAN LLP

        ________________

        Brian E. Farnan (#4089)

        919 North Market Street, 12th Flr

        Wilmington, DE 19801

        (302) 777-0336

        bfarnan@farnanlaw.com

         

        Attorneys for Plaintiff

        Enzo Life Sciences, Inc.
	MORRIS NICHOLS
ARSHT &TUNNELL LLP

______________________

Jack B. Blumenfeld (#1014)

Derek J. Fahnestock (#4705)

1201 North Market Street

P.O. Box 1347

Wilmington, DE 19899

(302) 658-9200

jblumenfeld@mnat.com

dfahnestock@mnat.com

Attorneys for Defendant

Agilent Technologies, Inc.Exhibit 10.2

 

SETTLEMENT AND LICENSE AGREEMENT

 

This SETTLEMENT AND LICENSE AGREEMENT (this
“Agreement”) is made and entered into as of May 16, 2016 (the “Effective Date”) by and between
Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having
offices at 10 Executive Boulevard, Farmingdale, NY 11735 (“Enzo”), and Defendant Life Technologies Corporation,
a corporation organized and existing under the laws of the State of Delaware, having offices at 5791 Van Allen Way, Carlsbad, California,
92008 (“Life”). Enzo and Life are individually referred to herein as a “Party,” and collectively
as the “Parties.”

 

WITNESSETH

 

WHEREAS, Enzo has alleged that Life infringes U.S. Patent Nos.
6,992,180 (the “180 patent”) and 7,064,197 (the “197 patent”) (collectively,
the “Patents-in-Suit”) in an action styled Enzo Life Sciences, Inc. v. Life Technologies Corporation, No.
1:12-cv-105-LPS, pending in the United States District Court for the District of Delaware (the “Litigation”)
and

 

WHEREAS, Life has alleged that it does not infringe either the
‘180 patent or the ‘197 patent, and further, that the ‘180 patent and the ‘197 patent are invalid and unenforceable;
and

 

WHEREAS, Enzo disputes Life’s allegations of invalidity,
unenforceability, and non-infringement; and

 

WHEREAS, the Parties now desire to settle the Litigation and
to provide and receive certain releases, licenses and covenants not to sue, all on the terms and conditions set forth herein; and

 

WHEREAS, this Agreement reflects a settlement and compromise
between the Parties under Federal Rule of Evidence 408 with respect to Enzo’s claims and defenses and Life’s counterclaims
and defenses in the Litigation, including without limitation on the disputed issues of patent validity, enforceability, and infringement;

 

NOW, THEREFORE, in consideration of the above promises and mutual
covenants hereinafter contained, the Parties agree as follows:

 

SECTION 1: DEFINITIONS

 

As used in this Agreement, the following terms shall have the
following meanings:

 

“Accused Life ‘180 Products” means
(1) all past and current products that, as of the Effective Date, have been and/or are made, used, imported, sold, and/or offered
for sale by Life or its Affiliates that have been accused of infringing the ‘180 patent in the Litigation; (2) any past or
current products made, used, imported, sold, and/or offered for sale by Life or its Affiliates that operate in substantially the
same manner as the products in (1) with respect to the inventions claimed in the ‘180 Patent and/or infringement theories
set forth in Enzo’s Infringement Contentions and Infringement Charts to Life in the Litigation concerning the ‘180
patent; and (3) any future products made, used, imported, sold, and/or offered for sale by Life or its Affiliates

    	1

    	

    

that are comparable to (1), insofar as they operate in substantially
the same manner with respect to the inventions claimed in the ‘180 Patent and/or Enzo’s Infringement Contentions and
Infringement Charts to Life in the Litigation. For the avoidance of doubt under this Agreement, “Accused Life ‘180
Products” includes, without limitation, Life’s past and current TaqMan Gene Expression assays, TaqMan SNP Genotyping
assays, TaqMan Drug Metabolism Genotyping Assays, TaqMan Copy Number Variation assays, TaqMan Mutation Detection Assays, TaqMan
MicroRNA assays, TaqMan siRNA assays, TaqMan Non-coding RNA assays, Custom TaqMan Probes, and Custom TaqMan assays, including Custom
TaqMan Gene Expression assays, Custom TaqMan SNP Genotyping Assays, and Custom and Custom Plus TaqMan Copy Number assays, and Custom
TaqMan Small RNA assays. For the avoidance of doubt, and notwithstanding anything to the contrary herein, Molecular Beacon Probes
are not within the scope of “Accused Life ‘180 Products.”

 

“Accused Life ‘197 Products” means
(1) all past and current products that, as of the Effective Date, have been and/or are made, used, imported, sold, and/or offered
for sale by Life or its Affiliates that have been accused of infringing the ‘197 patent in the Litigation; (2) any past or
current products made, used, imported, sold, and/or offered for sale by Life or its Affiliates that operate in substantially the
same manner as the products in (1) with respect to the inventions claimed in the ‘197 Patent and/or infringement theories
set forth in Enzo’s Infringement Contentions and Infringement Charts to Life in the Litigation concerning the ‘197
patent; and (3) any future products made, used, imported, sold, and/or offered for sale by Life or its Affiliates that are comparable
to (1), insofar as they operate in substantially the same manner with respect to the inventions claimed in the ‘197 Patent
and/or Enzo’s Infringement Contentions and Infringement Charts to Life in the Litigation. For the avoidance of doubt under
this Agreement, “Accused Life Products” includes, without limitation, Life’s past and current Dynabeads Oligo
(dT)25 (all sizes), Dynabeads mRNA DIRECT kits, Dynabeads mRNA Purification kits, Dynabeads® mRNA DIRECTTM Micro Purification
Kit; Ion Proton I Chip (all versions), Ion PI Chip Kits (all versions and sizes), Ion 314 Chip Kits (all versions and sizes), Ion
318 Chip Kits (all versions and sizes), and Ion 316 Chip Kits (all versions and sizes); SOLiD 6-Lane Flow Chip; 5500 W FlowChip
V2; NCode Human miRNA Microarray V3, NCode Multi-Species miRNA Microarray Kit V2, and NCodeTM Multi-Species miRNA Pre-printed
Microarrays; and NCode Non-coding RNA assay, NCode Human Non-coding RNA Microarrays, and NCode Mouse Non-coding RNA Microarrays;
and the “Stricken Life Products” listed in Exhibit 1 of the district court’s January 12, 2015 order. For the
avoidance of doubt, and notwithstanding anything to the contrary herein, Molecular Beacon Probes are not within the scope of “Accused
Life ‘197 Products.”

 

“Affiliate” means, with respect to a Party,
any Person that, as of the Effective Date, is directly or indirectly controlling, controlled by, or under common control with,
such Party. For purposes of this Agreement, “control” means the direct or indirect ability to control or direct the
management and operations of the subject Person, whether through ownership, contract or otherwise. Control will be presumed where
a Party has ownership, direct or indirect, of 50% or more of the outstanding voting shares, securities, equity, interest or other
ownership of the Person. Notwithstanding anything to the contrary herein, the following Persons are not, and cannot be considered,
Affiliates of Life for the purposes of this Agreement so long as any patent infringement litigation or royalty obligation concerning
the Licensed Enzo Patents remains

    	2

    	

    

pending between Enzo and that Person (or any Affiliate of that
Person): Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm
Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Roche
Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics
Operations Inc. (part of Hoffmann-La Roche AG); Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); and Luminex Corporation;
or their respective Affiliates.

 

“Covered Third Party Accused Products” means
Third Party products and services that include as an element thereof any Accused Life ‘180 Product or Accused Life ‘197
Product.

 

“Diagnostic Uses, Applications, and/or Embodiments”
means (1) uses, applications, and/or embodiments of in vitro diagnostic assays approved by an applicable governmental authority
(e.g., U.S. Food and Drug Administration, or comparable state or non-U.S. body) for use in the applicable territory for determining
or assessing a state of health or disease, or a risk of disease, in a human being, in the medical management of a human being,
in an animal, or in the medical or commercial management of an animal, but only to the extent actually sold or used for any such
approved use; and (2) uses, applications, and/or embodiments for in vitro screening of samples that are approved by an applicable
governmental authority (e.g., U.S. Food and Drug Administration, or comparable state or non-U.S. body) for use in the applicable
territory for the purpose of assessing suitability for blood and/or tissue banking, but only to the extent actually sold or used
for any such approved use. For the avoidance of doubt, any prior, existing, and/or future manufacturing, use, and/or sale of a
product that at the time of such manufacturing, use, and/or sale is not for a use, application and/or embodiment within the scope
of foregoing (1) or (2) but is subsequently used or sold for a use, application and/or embodiment that is within the scope of foregoing
(1) or (2) is within the definition of “Diagnostic Uses, Applications, and/or Embodiments.”

 

“Enzo Products” means (1) all past and current
products that, as of the Effective Date, have been and/or are made, used, imported, sold, and/or offered for sale by Enzo or its
Affiliates; (2) any past or current products made, used, imported, sold, and/or offered for sale by Enzo or its Affiliates that
embody, are substantially similar to, or operate in substantially the same manner with respect to the inventions claimed in patents
owned or licensed by Life or its Affiliates; and (3) any future products made, used, imported, sold, and/or offered for sale by
Enzo or its Affiliates that are comparable to (1), insofar as they operate in substantially the same manner with respect to the
inventions claimed in patents owned or licensed by Life or its Affiliates.

 

“Enzo’s Infringement Contentions and Infringement
Charts” means any and all contentions and/or infringement charts argued or presented by Enzo as part of the Litigation,
including without limitation those contentions and infringement charts attached hereto as Exhibit B.

 

“Licensed Enzo Patents” means Licensed Enzo
‘180 Patents and Licensed Enzo ‘197 Patents.

 

“Licensed Enzo ‘180 Patents” means
(i) U.S. Patent No. 6,992,180; (ii) any patents and patent applications claiming priority to or through the patents listed in subparts
(i); (iii) any patents and patent applications to which any of the patents and patent applications covered in subparts (i) and

    	3

    	

    

(ii) claim priority; and (iv) any foreign counterparts, re-issues,
re-examinations, renewals, substitutes, claim amendments made in post-grant proceedings including IPR and PGR proceedings, extensions,
continuations, continuations-in-part, continuing prosecution applications, divisionals, and national phase filings of any patents
and patent applications covered in subparts (i), (ii) and (iii).

 

“Licensed Enzo ‘197 Patents” means
(i) U.S. Patent No. 7,064,197; (ii) any patents and patent applications claiming priority to or through the patents listed in subparts
(i); (iii) any patents and patent applications to which any of the patents and patent applications covered in subparts (i) and
(ii) claim priority; and (iv) any foreign counterparts, re-issues, re-examinations, renewals, substitutes, claim amendments made
in post-grant proceedings including IPR and PGR proceedings, extensions, continuations, continuations-in-part, continuing prosecution
applications, divisionals, and national phase filings of any patents and patent applications covered in subparts (i), (ii) and
(iii).

 

“Enzo Patents” means (i) all patents and
patent applications owned, controlled, or filed by or assigned to Enzo or its Affiliates as of the Effective Date; (ii) any patents
and patent applications claiming priority to or through any of the foregoing; (iii) any patents and patent applications to which
any of the patents and patent applications covered in subparts (i) and (ii) claim priority; and (iv) any foreign counterparts,
re-issues, re-examinations, renewals, substitutes, claim amendments made in post-grant proceedings including IPR and PGR proceedings,
extensions, continuations, continuations-in-part, continuing prosecution applications, divisionals, and national phase filings
of any patents and patent applications covered in subparts (i), (ii) and (iii).

 

“Immaterial Acquired Third Party” means a
Third Party acquired by Life or its Affiliates for fifty million U.S. Dollars ($50,000,000) in the aggregate or less in cash, stock,
assumption of liability, or other consideration of equivalent value. For purposes of this agreement, the following entities and
Affiliates thereof shall not qualify as an Immaterial Acquired Third Party for so long as any patent infringement litigation or
royalty obligation concerning the Licensed Enzo Patents exists between Enzo and any such entity or Affiliates or successors thereof:
Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences,
Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Roche Molecular
Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations
Inc. (part of Hoffmann-La Roche AG); Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG).

 

“Licensed Life Products” means any past,
current and future products and services, product lines, devices, instruments, systems, assays, components, kits, hardware, software,
or any combination of the foregoing which are made, used, imported, exported, distributed, sold, or offered for sale by Life or
its Affiliates.

 

“Life Released Parties” means (a) Life and
its parents, subsidiaries, predecessors, permitted successors, and permitted assigns(but only, with respect to permitted successors
and assigns, to the extent related to the Licensed Life Products), (b) all Affiliates, directors, officers, individual

 

    	4

    	

    

shareholders, attorneys, and employees of the persons in (a)
solely to the extent of such party’s involvement, on behalf of, Life in developing, making, using, or importing any Licensed
Life Products, (c) any and all distributors, resellers, customers, purchasers and/or end users of any Licensed Life Products, but
solely to the extent of their purchase, possession, use or resale of Licensed Life Products directly or indirectly from Life or
its Affiliates, (d) permitted successors and assigns of the foregoing, but only to the extent that their potential liability derives
from Licensed Life Products, and (e) vendors, suppliers, manufacturers, developers, original equipment manufacturers, contractors,
and agents, solely to the extent of such party’s involvement, on behalf of Life, in developing, making, using, or importing
any Licensed Life Products. Notwithstanding anything to the contrary above, for purposes of this agreement, none of the following
entities (nor their Affiliates and/or successors) shall be deemed a Life Released Party for so long as any patent infringement
litigation or royalty obligation concerning the Licensed Enzo Patents exists between Enzo and any such entity or Affiliates thereof:
Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences,
Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Roche Molecular
Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations
Inc. (part of Hoffmann-La Roche AG); Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG).

 

“Material Acquired Third Party” means a Third
Party acquired by Life or its Affiliates for greater than fifty million U.S. Dollars ($50,000,000) in cash, stock, assumption of
liability, or other consideration of equivalent value. For purposes of this agreement, each of the following entities and Affiliates
and successors thereof shall be deemed a Material Acquired Third Party for so long as any patent infringement litigation or royalty
obligation concerning the Licensed Enzo Patents exists between Enzo and any such entity of Affiliates thereof: Abbott Laboratories;
Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of
Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Roche Molecular Systems, Inc. (part
of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part
of Hoffmann-La Roche AG); Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG).

 

“Molecular Beacon Probes” means stem loop
nucleic acid hybridization probes having interacting FRET (Förster/fluorescence resonance energy transfer) labels/dyes/moieties
disposed in the stem region(s) of the probe, which FRET labels/dyes/moieties become more distant to each other upon hybridization
of such a probe to a target nucleic acid. For clarity, TaqMan probes are not Molecular Beacon Probes.

 

“Payment” has the meaning set forth in Section
3.1.

 

“Person” means an individual, trust, corporation,
partnership, joint venture, limited liability company, association, unincorporated organization or other legal entity.

 

“Third Party” means any Person or entity
other than the Parties to this Agreement and their Affiliates.

    	5

    	

    

“Uncovered Products” means Accused Life ‘180
Products and Accused Life ‘197 Products used by Life or its Affiliates that are not or have not been made, imported, sold,
or offered for sale by, for or on behalf of Life or its Affiliates.

 

SECTION 2: LICENSE, RELEASES AND
COVENANTS

 

2.1 License. Upon Life’s payment of the Payment,
Enzo hereby grants to Life Released Parties a fully paid-up, non-exclusive, non-transferable (except as set forth in Section 5),
worldwide license solely under and with respect to the Licensed Enzo Patents in all fields to make, have made, use, import, export,
distribute, sell, have sold, offer for sale, and practice all processes and methods in connection with, the Licensed Life Products.

 

Enzo further grants Life Released Parties a license solely under
and with respect to the Licensed Enzo Patents to (a) convey to customers the right to use the Licensed Life Products and practice
all processes and methods in connection with such Licensed Life Products under the Licensed Enzo Patents, (b) employ Third Party
distributors to sell Licensed Life Products under the Licensed Enzo Patents; (c) convey to Third Parties the right to re-sell Licensed
Life Products purchased from Life Released Parties under the Licensed Enzo Patents, (d) employ Third Party contract manufacturers
to make or otherwise use, on behalf of Life or its Affiliates, Licensed Life Products under the Licensed Enzo Patents, and (e)
convey to Third Parties the right to combine or otherwise use Licensed Life Products with other products or components under the
Licensed Enzo Patents but such rights shall not extend to Covered Third Party Products that would give rise to an independent claim
of infringement of the Licensed Enzo Patents against such Third Party. None of the foregoing will be construed as a sublicense.
For the avoidance of doubt, Enzo does not confer any rights or covenants to the Licensed Enzo Patents to Third Party contract manufacturers
with respect to any products other than the Licensed Life Products or to any conduct or activity by Third Party contract manufacturers
not performed on behalf of Life or its Affiliates.

 

Except as expressly set forth herein, Life does not have the
right to sublicense or otherwise grant, in whole or in part, licenses under the Licensed Enzo Patents.

 

2.2 Enzo Release of Life Released Parties. Subject to
Life’s payment of the Payment and agreement not to seek repayment of same, Enzo, on behalf of itself and its Affiliates,
releases, acquits and absolutely and forever discharges the Life Released Parties, from any claim, counterclaim, demand, allegation,
damage, loss, debt, liability, account, reckoning, indemnity, obligation, cost, expense, lien, attorneys’ fee, any other
action or cause of action of any kind or nature, whether now known or unknown, suspected or unsuspected, matured or unmatured,
asserted or unasserted, in law or equity, for (i) infringement of the Licensed Enzo Patents by or on behalf of Life Released Parties
to the extent occurring before the Effective Date; (ii) claims and counterclaims made, asserted or brought in, or that could have
been made, asserted, or brought under the Licensed Enzo Patents; and (iii) the conduct of settlement negotiations (except for representations
or obligations expressly included in this Agreement); provided, however, that Life Released Parties other than Life and its Affiliates
shall not be released from liability for

    	6

    	

    

infringement that Enzo could not have directly or indirectly
brought against Life or its Affiliates themselves. For the avoidance of doubt, any conduct or activity by Life Released Parties
not performed on behalf of or as intended by Life or its Affiliates is expressly excluded from this Section 2.2. Notwithstanding
anything to the contrary above, for purposes of this agreement, none of the following entities (nor their Affiliates and/or successors)
shall be deemed released from any liability to Enzo by virtue of this paragraph: Abbott Laboratories; Abbott Molecular, Inc.; Becton,
Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc.
(now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Roche Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche
Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La Roche AG); Roche
Nimblegen, Inc. (part of Hoffmann-La Roche AG).

 

2.3 Enzo Covenant Not to Sue Life Released Parties. Subject
to Life’s payment of the Payment, Enzo, on behalf of itself and its Affiliates, covenants during the term of this Agreement
not to directly or indirectly commence or prosecute, cause to be commenced or prosecuted, or assist in the commencement or prosecution
of any action, suit, arbitration, or proceeding of any kind anywhere in the world against any of the Life Released Parties for
infringement of any of (i) the Licensed Enzo Patents practiced in any field; or (ii) the Enzo Patents by the Accused Life ‘180
Products or Accused Life ‘197 Products except for Diagnostic Uses, Applications, and/or Embodiments or by Uncovered Products;
provided, however, that Life Released Parties other than Life and its Affiliates shall not be released from, and this Covenant
Not to Sue shall not extend to matters concerning, liability for infringement that Enzo could not have brought against Life or
its Affiliates themselves. Notwithstanding the foregoing, if Life Released Parties or any permitted successors, assigns, or other
Person who permissibly assumes Life’s rights and obligations under this Agreement directly or indirectly commences or causes
to be commenced any action, suit, arbitration, or proceeding of any kind anywhere in the world against Enzo or its Affiliates for
infringement of a patent owned or licensed by Life or its Affiliates as of the Effective Date by an Enzo Product for Diagnostic
Uses, Applications, and/or Embodiments, then subsection (ii) of the foregoing Covenant Not to Sue shall immediately terminate,
be deemed null and void ab initio, and be of no force and effect except if patent infringement is raised by Life or its
Affiliates as a counterclaim or defense. Any such termination under subsection (ii) of the Covenant Not to Sue Life Released Parties
shall not apply to the foregoing subsection (i) (the covenant not to sue Life Released Parties for infringement of the Licensed
Enzo Patents). This section 2.3 does not impact Enzo’s ability to prosecute action under Section 6.5. For the avoidance of
doubt, Enzo does not confer any rights or covenants to the Enzo Patents to Third Party contract manufacturers with respect to any
products other than the Licensed Life Products or to any conduct and/or activity by Third Party contract manufacturers not performed
on behalf of Life of its Affiliates. Notwithstanding anything to the contrary above, for purposes of this agreement, none of the
following entities (nor their Affiliates and/or successors) shall be deemed subject to the covenants set forth in this paragraph
for so long as any patent infringement litigation or royalty obligation concerning the Licensed Enzo Patents exists between Enzo
and any such entity or Affiliates thereof: Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton,
Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.);
Hologic, Inc.; Illumina, Inc.; Roche Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics

    	7

    	

    

Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics
Operations Inc. (part of Hoffmann-La Roche AG); Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG).

 

2.4 Life Release of Enzo. Life, on behalf of itself and
its Affiliates, releases, acquits and absolutely and forever discharges Enzo and its Affiliates, officers, directors, shareholders,
managers, employees, agents, and attorneys from any claim, counterclaim, demand, allegation, damage, loss, debt, liability, account,
reckoning, indemnity, obligation, cost, expense, lien, attorneys’ fee, any other action or cause of action of any kind or
nature, whether now known or unknown, suspected or unsuspected, matured or unmatured, asserted or unasserted, in law or equity,
arising out of or related to: (i) the Licensed Enzo Patents; (ii) the claims, defenses, and counterclaims asserted in, and the
conduct of, the Litigation; and (iii) the conduct of settlement negotiations (except for representations or obligations expressly
included in this Agreement); provided, however, that Life does not release and preserves the right to raise any and all defenses
and counterclaims, including, but not limited to, invalidity and unenforceability of the Licensed Enzo Patents, that it could have
raised in the Litigation, and to otherwise contest the validity and enforceability of the Licensed Enzo Patents in any forum, if
a Licensed Enzo Patent is asserted against Life Released Parties after the Effective Date in an action not initiated by any of
the Life Released Parties.

 

2.5 Covenant Not to Challenge. After the Effective Date
and for so long as Life’s license is in force, Life further covenants that, except as (1) required by law or (2) in defense
of a threatened or actual action, suit or proceeding of any kind alleging a claim for infringement of any Licensed Enzo Patents
brought against any Life Released Parties, it shall not knowingly and voluntarily contest, or assist in the contest, or encourage
any other Person to contest, in any forum, including Federal Courts, whether under 28 U.S.C. §§ 2201-2202 or not, the
United States Patent and Trademark Office, and/or the International Trade Commission, that the Licensed Enzo Patents are valid
and enforceable; provided, however, nothing in this Agreement shall prevent Life or its Affiliates from complying with or responding
to any court or governmental order or subpoena relating to the Licensed Enzo Patents. Notwithstanding the foregoing, nothing in
this Agreement will preclude Life and its Affiliates from making any disclosure, providing information or producing documents as
required by law, court order or legal process (including, without limitation, litigation related to discovery and/or subpoena),
even if made in connection with a proceeding challenging the validity or enforceability of one or more of the Licensed Enzo Patents,
and any such disclosure will not be considered a breach of this Agreement. It is understood that Life’s and its Affiliates’
providing factual statements regarding Licensed Life Products or any Third Party products containing them in response to a validly
propounded subpoena, will not be considered as assisting in the contest as used above. Life and its Affiliates reserve the right
to raise any and all defenses and counterclaims, including, but not limited to, invalidity and unenforceability of the Licensed
Enzo Patents, and to otherwise contest the validity and enforceability of the Licensed Enzo Patents in any forum, that it could
have raised in the Litigation, if any of the Licensed Enzo Patents is asserted based on Licensed Life Products against Life Released
Parties after the Effective Date; and Enzo reserves the right to raise any and all claims and defenses in opposition.

 

2.6 After-acquired Entities. The releases, licenses and
covenants not to sue, and their scope, as set forth herein apply to any Immaterial Acquired Third Party acquired by Life or its
Affiliates

    	8

    	

    

(whether by merger, consolidation, share acquisition, or acquisition
of all or substantially all assets or otherwise) after the Effective Date. The licenses, releases, and covenants set forth above
shall not apply to and shall exclude any products of any Material Acquired Third Party that is acquired by Life or its Affiliates
(whether by merger, consolidation, share acquisition, or acquisition of all or substantially all assets or otherwise) on or after
the Effective Date; provided, however, that this provision will not derogate from any right, privilege, or immunity such Person
may already have under the Licensed Enzo Patents. The Parties recognize that Life has entered into a transaction whereby Affymetrix,
Inc. will become an Affiliate of Life and, upon the close of such transaction, the rights, covenants, privileges, and immunities
mutually granted in this Agreement shall extend to products and services of Affymetrix, Inc. and its Affiliates.

 

2.7 No Extinguishment Of Other Outstanding Royalty Obligations.
For the avoidance of doubt, nothing in this Agreement shall operate to extinguish the obligation of any Person to pay royalties
to Enzo arising from an obligation outside of this Agreement (including via contract, operation of law, judicial ruling, or otherwise).

 

2.8 No Other Rights. No rights or covenants are granted
under any patents except as expressly provided herein, whether by implication, estoppel or otherwise. No right to grant covenants,
rights, sublicenses, or to become a foundry for Third Parties is granted under this Agreement. For the avoidance of doubt, Enzo
does not confer any rights or covenants to the Licensed Enzo Patents or Enzo Patents to Third Party contract manufacturers with
respect to products other than the Licensed Life Products or to any conduct or activity by Third Party contract manufacturers not
performed on behalf of Life of its Affiliates. The Parties agree that, except as expressly set forth elsewhere in this Agreement,
the licenses, releases and covenants set forth in this Agreement (including Section 2) expressly exclude any methods, systems,
products, services and/or components of any Third Party and this Agreement does not cut off Enzo’s rights to enjoin, control
or extract royalties with respect to such Third Party’s methods, systems, products, services and/or components.

 

2.9 Waiver of California Civil Code Section 1542. It
is the intention of the Parties in executing this Agreement that this Agreement is effective as a full and final accord and satisfaction
and mutual release of the matters set forth in Sections 2.2 and 2.4. Each of the releases set forth in Sections 2.2 and 2.4 constitutes
a waiver of any and all rights under California Civil Code Section 1542 (and any similar or analogous requirement of law), to the
extent Section 1542 otherwise would apply. The parties understand that Section 1542 provides as follows:

 

A general release does not extend to claims which the creditor
does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have
materially affected his or her settlement with the debtor.

 

SECTION 3: MONETARY CONSIDERATION

 

3.1 Payment. As partial consideration for this Agreement
and the dismissal by Enzo of the Litigation against Life hereunder, Life agrees to pay to Enzo a total of thirty-five million U.S.

    	9

    	

    

Dollars ($35,000,000) (“Payment”), payable
by Life to Enzo no later than seven (7) business days following the Effective Date of this Agreement in lawful money of the United
States, in immediately available funds, by wire transfer to the following account: # # #

 

3.2 Taxes / Costs. Each Party acknowledges that this
Agreement may have U.S. federal and state tax (collectively, “Tax”) or other consequences, and that the Party
is not relying on any other Party for advice, representations or communications as to any potential Tax or other consequences.
This Agreement is enforceable regardless of its Tax or other consequences. The Parties agree that they shall bear their own costs
and attorneys’ fees relating to or arising from the Litigation and to the documentation and negotiation of this Agreement.

 

3.3 Dismissal. Within three
(3) court days after the Payment to Enzo under this Section 3 has cleared, the Parties shall cause their respective counsel
to execute and file the stipulated motion in the form set forth in Exhibit A dismissing with prejudice all of
Enzo’s claims and counterclaims against Life in the Litigation and dismissing without prejudice all of Life’s
claims and counterclaims against Enzo in the Litigation. The Parties shall promptly proceed with any and all additional
procedures needed to dismiss the Litigation as set forth above, with each Party to bear its own costs and attorneys’
fees. The Parties also agree to submit to the court appropriate stipulations and proposed orders for extensions of time for
all due dates in the Litigation so that neither Party is required to incur unnecessary expenses in the Litigation between the
Effective Date and the date the Litigation is dismissed. The Parties acknowledge and agree that this Agreement is enforceable
according to its terms with respect to final dismissal of all claims and counterclaims in the Litigation.

 

3.4 No Admission of Liability. This Agreement is the
result of a compromise and will not at any time be considered as an admission of liability or responsibility, or lack thereof,
on the part of Enzo or Life. By entering into this Agreement, neither Life nor any of its Affiliates is conceding that it acted
wrongfully in any fashion whatsoever. Except as expressly set forth in Section 3.1, Life and its Affiliates expressly deny that
they are liable to Enzo in any way.

 

3.5 Full Settlement. The Parties agree that this Agreement
is in full and complete settlement of the remaining rights and obligations between the Parties in connection with the Litigation.
This Agreement may be pleaded as a defense to any action, suit or claim and may be used as a basis for an injunction against any
such action, suit, claim, or other proceeding of any type which may be prosecuted, initiated or attempted in violation of the terms
hereof. A Party is entitled to recover from the other adverse Party reasonable attorneys’ fees and other related legal expenses
incurred in defending against any suit, action or claim brought or attempted by the other Party in violation of the terms of this
Agreement

    	10

    	

    

SECTION 4: TERM AND TERMINATION

 

4.1 Term. The term of this Agreement shall commence upon
the Effective Date and shall continue until the expiration of the enforceability period for the last-to-expire of the Enzo Patents,
unless earlier terminated as set forth in Section 4.2 below.

 

4.2 Termination. If Life fails to make the Payment set
forth in Section 3.1 in the time frame required by Section 3.1, then Enzo may terminate this Agreement immediately upon further
written notice to that effect and the license, releases, and covenants granted by Section 2 of this Agreement shall immediately
terminate, be deemed null and void ab initio, and be of no force and effect. Once the payment set forth in Section 3.1 is
made, this Agreement (including the licenses, releases and dismissals in this Agreement) will be irrevocable and non-terminable
except by written agreement of all of the Parties.

 

SECTION 5: ASSIGNMENT

 

5.1 Assignment. The license and other rights granted
by Enzo in this Agreement are personal to Life. Except as expressly permitted in this Section, Life may not assign, delegate, or
otherwise transfer this Agreement or any license or rights hereunder without the prior written consent of Enzo. The limitations
on assignment set forth in Section 5 do not apply to an internal reorganization of a Party or its Affiliates (re-incorporation,
internal re-structuring or the like) and written notice or consent of Enzo is not required for any such internal reorganization.
Any other assignment, delegation, or transfer without the prior written consent of Enzo (except as expressly permitted in this
Section 5) will be null and void ab initio and without effect.

 

5.2 Permitted Assignment by Life. Notwithstanding the
provisions of Section 5.1, Life may assign its rights under this Agreement, in whole or in part, without Enzo’s prior written
consent, to a Person that acquires all or part of Life’s business or assets at issue in the Litigation; provided, however,
that (1) this Agreement may be assigned to multiple Persons, but only to extent that each Person acquires the part of Life’s
business or assets; (2) any such assignment of rights will not extend to products or services of the acquiring Person that pre-existed
the acquisition (or natural evolutions or extensions thereafter) but will not derogate from any right, privilege or immunity such
Party may already have under Enzo Patents; (3) any such assignment of rights shall not relieve the acquiring Person from any obligations
that such Person may have under this Agreement; and (4) Life obtains from the acquiring Person a written agreement to be bound
by the terms and conditions of this Agreement and furnishes the same to Enzo. In the event that Life is not acquired in its entirety
or does not continue to exist as a distinct operating entity (such as a wholly-owned subsidiary) after the acquisition, the rights
of Life hereunder so assigned only extend to Licensed Life Products existing as of the date of the acquisition and natural evolutions
of Licensed Life Products created after the date of the acquisition, and will not otherwise extend to any products, services or
activities of the acquiring Person prior to, on or after the date of the acquisition. The releases and covenants provided by Life
and its Affiliates shall run with the rights being assigned or transferred and shall be binding on any permitted successors-in-interest,
transferees, or assigns thereof. For avoidance of doubt, any such assignment of rights will not extend to any Material Acquired
Third Party products or services

    	11

    	

    

existing prior to the time of acquisition or natural evolutions
or extensions thereafter; provided, however, that this provision will not derogate from any right, privilege, or immunity such
Person may already have under the Licensed Enzo Patents. Any purported assignment, delegation, or transfer under Section 5.2 that
does not comply with the foregoing will be null and void ab initio and without effect.

 

5.3 Further Restriction on Assignment by Life. Notwithstanding
the provisions of Sections 5.1 and 5.2, in no event may this Agreement or any licenses or rights hereunder be assigned, delegated,
or otherwise transferred without Enzo’s prior written consent to any of the following: Abbott Laboratories; Abbott Molecular,
Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson);
Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Roche Molecular Systems, Inc. (part of Hoffmann-La
Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La
Roche AG); Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); and Luminex Corporation; or their respective Affiliates, so long
as any of the concurrently pending patent infringement litigations concerning the Licensed Enzo Patents remains pending between
Enzo and the respective aforementioned entity (or any Affiliate thereof). For the avoidance of doubt, a Third Party’s acquisition
of Life by stock purchase, reverse triangular merger, or similar transaction does not constitute an assignment of the Agreement
by Life where Life continues to exist as a distinct operating entity (for example, as a wholly-owned subsidiary) after the acquisition
and does not expressly assign the Agreement to any other entity, provided that the licenses, covenants, and releases granted herein
shall extend only to Licensed Life Products existing as of the date of the acquisition and natural evolutions of Licensed Life
Products created by the Life distinct operating entity after the date of the acquisition, and will not otherwise extend to any
products, services or activities of the acquiring Third Party prior to, on or after the date of the acquisition.

 

5.4 Permitted Assignment by Enzo. All license rights
and covenants contained herein shall run with the Licensed Enzo Patents and Enzo Patents, as such categories apply herein to the
license rights and covenants contained in Sections 2.1 through 2.6, inclusive, and shall be binding on any successors-in-interest
or assigns thereof. Any assignment of any of the Licensed Enzo Patents and Enzo Patents, or an exclusive license granted thereto,
to any other Person, including, but not limited to the right to license, enforce, and collect damages, shall be subject to this
Agreement. Any assignment of or exclusive license to any Licensed Enzo Patents or Enzo Patents shall be subject to the terms and
conditions in Sections 2.1 through 2.6.

 

SECTION 6: MISCELLANEOUS PROVISIONS

 

6.1 Representations.

 

6.1.1 Enzo Representations. Enzo represents
and warrants, to the best of its knowledge, that: (i) as of the Effective Date, Enzo and/or its Affiliates own, control, have filed,
or are assignees of the Enzo Patents, including the Licensed Enzo Patents, do not jointly own any of the Enzo Patents with any
other Person, and have the right to grant the license, releases and covenants with respect to the Enzo Patents, including the Licensed
Enzo Patents, of the full scope set forth herein; (ii) as of the Effective Date, it has not assigned or otherwise transferred to

    	12

    	

    

any other Person any rights to the Enzo Patents or Licensed
Enzo Patents that would prevent Enzo from conveying the full scope of rights set forth herein and has not filed any suit or proceeding
against Life or any Affiliate except as referenced (including in section 6.5) and/or released herein; (iii) the person executing
this Agreement on behalf of Enzo has the full right and authority to enter into this Agreement on Enzo’s behalf; and (iv)
apart from its contentions against Life concerning the Patents-in-Suit, as of the Effective Date of this Agreement, and without
having undertaken any specific investigation in connection with this representation, Enzo and its Affiliates are not aware of any
other intellectual property claim owned or controlled by Enzo or its Affiliates that is currently infringed by Life and/or its
Affiliates and that Enzo and its Affiliates have no intention as of the Effective Date to assert any known intellectual property
claims against Life and/or its Affiliates. Notwithstanding the foregoing, if any of Enzo’s patents are found invalid, this
shall not cause a breach of the foregoing representation regarding Enzo or its Affiliates’ right to grant the license, release,
or other rights provided herein.

 

6.1.2 Life Representations. Life represents
and warrants that: (i) as of the Effective Date, Life has the right to grant the releases and covenants of the full scope set forth
herein; and (ii) the person executing this Agreement on behalf of Life has the full right and authority to enter into this Agreement
on Life’s behalf.

 

6.1.3 Disclaimer of Representation.
Nothing in this Agreement shall be construed as (i) a representation or warranty by Enzo as the scope, validity, or enforceability
of any patent; (ii) a representation or warranty that the manufacture, use, or sale of any products will not utilize or infringe
any intellectual property rights; and (iii) any obligation by Enzo to pay annuities or otherwise maintain any patents in force
in any country.

 

6.2 Confidentiality. From and after the Effective Date,
neither Party nor any of its Affiliates shall disclose the terms of this Agreement without the prior written consent of the other
Party except:

 

6.2.1 to any governmental body having jurisdiction
and specifically requiring such disclosure;

 

6.2.2 in response to a valid document request
or subpoena or as otherwise may be required by law, legal process or order of a court, provided a protective order is in place
that limits disclosure of such information to outside counsel only and the disclosing Party provides the other Party with written
notice at least ten (10) business days prior to disclosure to permit the other Party the opportunity to object and/or to seek a
court-entered protective order or comparable court-ordered restriction, and shall reasonably cooperate with the other Party in
its efforts to obtain that protective order and take all other reasonable actions in an effort to minimize the nature and extent
of such disclosure and obtain confidential treatment to the extent available;

 

6.2.3 for the purposes of disclosure in connection
with securities exchange obligations, including the Securities and Exchange Act of 1934, as amended, the Securities Act of 1933,
as amended, and any other reports filed with the Securities and Exchange Commission (expressly

    	13

    	

    

including, but not limited to, Form 8K disclosures), or any
other filings, reports or disclosures that may be required under applicable laws or regulations;

 

6.2.4 to a Party’s or its controlling
Affiliates accountants, legal counsel, tax advisors, insurers, auditors and other financial and legal advisors and other professional
advisors in their capacity of advising the party in such matters, subject to obligations of confidentiality and/or privilege at
least as stringent as those contained herein;

 

6.2.5 with obligations of confidentiality
at least as stringent as those contained herein, to a counterparty in connection with a possible asset sales, investments, change
in control, merger, acquisition, financing or similar transaction;

 

6.2.6 in connection with tax audits or to
fulfill its corporate financial reporting obligations under GAAP;

 

6.2.7 with obligations of confidentiality
at least as stringent as those contained herein, by any Party and its Affiliates as required to enforce this Agreement or establish
rights hereunder;

 

6.2.8 to officers, key shareholders and/or
employees with a need to know, attorneys, accountants and directors, who are under obligations of confidentiality (which may include
professional responsibility obligations) at least as stringent as those contained herein;

 

6.2.9 to its Affiliates who are similarly
bound by this Agreement or under obligations of confidentiality at least as stringent as those contained herein; or

 

6.2.10 to Third Parties who make, sell, offer
to sell, import or distribute a Licensed Life Product or who make, sell, or offer to sell a Covered Third Party Accused Product,
and who have a need to know, under obligations of confidentiality at least as stringent as those contained herein. Notwithstanding
anything else in this Agreement to the contrary, a Party may also disclose to anyone any information that is publicly available,
through no breach by any Party of the confidentiality obligations hereunder.

 

6.3 Exceptions to Confidentiality Obligations. Notwithstanding
Section 6.2, the Parties agree that (i) the fact that the Litigation has been settled; and (ii) public statement that this Agreement
sets forth a compromise and settlement of disputed claims for the purpose of avoiding the costs, disruptions, and uncertainties
associated with further litigation, and such compromise and settlement does not constitute a ruling on the merits, an admission
as to any issue of fact or principle at law or an admission of liability of any Party, are not subject to the confidentiality provisions
of Section 6.2.

 

6.4 Notices. All notices required or permitted to be
given hereunder shall be in writing and shall be delivered by hand, or, if dispatched by prepaid air courier, with package tracing
capabilities or by registered or certified airmail, postage prepaid, addressed as follows:

    	14

    	

    

If to Enzo:

 

Dr. Elazar Rabbani

Enzo Life Sciences, Inc.

527 Madison Avenue

New York, NY 10022

 

Copy to (which does not constitute notice):

 

Michael Stadnick

Desmarais LLP

230 Park Avenue

New York, NY 10169

 

If to Life:

 

Life Technologies Corporation

5823 Newton Drive

Carlsbad, CA 92008

Tel: 760-603-7200

Attn: General Counsel

 

Copy to (which does not constitute notice):

 

Thermo Fisher Scientific Inc.

81 Wyman Street

Waltham, MA 02451

Attn: General Counsel

 

Such notices shall be deemed to have been given or served (a)
upon personal hand delivery, (b) one day after being sent by email with telephone confirmation of receipt, or (c) one day after
confirmed receipt from recognized express courier service that maintains such records of receipt. Either Party may give written
notice of a change of address and, after notice of such change has been received, any notice or request shall thereafter be given
to such Party as above provided at such changed address.

 

6.4 Governing Law / Jurisdiction. This Agreement and
matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance
with the laws of the United States of America and the State of Delaware, without reference to conflict of laws principles. Enzo
and Life agree (a) that all disputes and litigation regarding this Agreement, its construction and matters connected with its performance
be subject to the exclusive jurisdiction of the state and federal courts in the state of Delaware (the “Court”),
and (b) to submit any disputes, matters of interpretation, or enforcement actions arising with respect to the subject matter of
this Agreement exclusively to the Court. The Parties hereby waive any challenge to the jurisdiction or venue of the Court over
these matters.

 

6.5 No Impact on Other Litigations. For the avoidance
of doubt, nothing in this Agreement, including without limitation, the licenses, releases, and covenants not to sue above, shall
be

    	15

    	

    

interpreted to affect, limit or preclude in any way, explicitly
or by implication, any other pending litigation involving any of Enzo, Enzo Biochem, Inc., Applera Corporation, Yale University
and/or any of their predecessors, successors, Affiliates or related parties, including but not limited to Enzo Biochem, Inc.
and Enzo Life Sciences, Inc., and Yale University v. Applera Corp. and Tropix, Inc. (D. Conn.), Case No. 3-04-CV-929.

 

6.6 Sophisticated Parties Represented by Counsel. The
Parties each warrants and represents that (i) it is a sophisticated party represented at all relevant times during the negotiation
and execution of this Agreement by counsel of their choice, and that they have executed this Agreement with the consent and on
the advice of such independent legal counsel; (ii) they and their counsel have determined through independent investigation and
robust, arm’s-length negotiation that the terms of this Agreement shall exclusively embody and govern the subject matter
of this Agreement; (iii) they investigated the facts pertinent to this Agreement as they deemed necessary; (iv) no other Person
or Party, nor any agent or attorney of a Party, made any promise, representation or warranty whatsoever, express or implied, not
contained in this Agreement concerning the subject matter of this Agreement to induce them to execute this Agreement; (v) they
have not executed this Agreement in reliance on any promise, representation or warranty whatsoever, express or implied, not contained
in this Agreement concerning the subject matter of this Agreement; and (vi) they have not executed this Agreement in reliance on
any promise, representation or warranty not contained herein. The Parties included this paragraph to preclude any claim that any
Party was fraudulently induced to execute this Agreement and to preclude the introduction of parol evidence to vary, interpret,
supplement or contradict the terms of this Agreement.

 

6.7 Bankruptcy. The Parties acknowledge and agree that
all rights and licenses granted by Enzo under or pursuant to this Agreement are, and will otherwise be deemed to be, for purposes
of Section 365(n) of the United States Bankruptcy Code, as amended (the “Bankruptcy Code”), licenses of rights
to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that, notwithstanding
anything else in this Agreement, Life and its Affiliates, as the licensee of such intellectual property rights under this Agreement,
will retain and may fully exercise all of its rights and elections under the Bankruptcy Code (including, without limitation, a
Life and its Affiliates’ right to the continued enjoyment of the rights and licenses granted by Enzo under this Agreement).
Further, this provision shall not alleviate or contravene the restrictions on assignments and acquisitions set forth in this Agreement.

 

6.8 No Laundering. The Parties understand and acknowledge
that the licenses, releases, and covenants granted to Life and its Affiliates by Enzo hereunder are intended to cover only the
bona fide products or services of Life and its Affiliates and are not intended to cover patent laundering activities (i.e., activities
that are undertaken solely for the purpose of improperly extending licensed rights to cover any activity of any third party acting
outside the scope of Life’s or its Affiliates’ licensed activities). The Parties further agree that a purchase of a
product from a supplier and resale of such product in substantially the same form back to the same supplier is not licensed under
this Agreement. Notwithstanding the foregoing, the combination of such supplied product with a Licensed Life Product and/or rebranding
of such combination and resale back to the supplier is not a prohibited resale of such product. Nothing in this Agreement shall
be construed to license sham sales or sham service contracts executed by Life or any of its

    	16

    	

    

Affiliates with any third party solely for the purpose of improperly
extending licensed rights to cover any activity of any third party acting outside the scope of Life’s (or its Affiliates’)
licensed activities.

 

6.9 Severability. If any provision of this Agreement
is held to be illegal or unenforceable, such provision shall be limited or eliminated to the minimum extent necessary so that the
remainder of this Agreement will continue in full force and effect and be enforceable. The Parties agree to negotiate in good faith
an enforceable substitute provision for any invalid or unenforceable provision that most nearly achieves the intent of such provision.

 

6.10 Entire Agreement. The Parties hereby agree that
(i) this is an enforceable agreement; (ii) this Agreement constitutes the entire and only understanding of each of them with respect
to the subject matter of the Agreement, and merges, supersedes and cancels all previous agreements and understandings, whether
oral or written, with respect to the subject matter of the Agreement; (iii) no oral explanation or oral information by any Party
hereto shall alter the meaning or interpretation of this Agreement; (iv) the terms and conditions of this Agreement may be altered,
modified, changed or amended only by a written agreement that identifies itself as an amendment to this Agreement and is executed
by duly authorized representatives of Enzo and Life; (v) the language of this Agreement has been approved by counsel for each of
them, and shall be construed as a whole according to its fair meaning; and (vi) none of the them (nor their respective counsel)
shall be deemed to be the draftsman of this Agreement in any action which may hereafter arise with respect to the Agreement. This
Agreement and any amendments hereto may be executed in one or more counterparts, each of which is deemed to be an original, but
all of which together constitute one instrument.

 

6.11 Modification; Waiver. No modification or amendment
to this Agreement, nor any waiver of any rights, will be effective unless assented to in writing by the Party to be charged, and
the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.

 

6.12 Construction; Language. Any rule of construction
to the effect that ambiguities are to be resolved against the drafting Party will not be applied in the construction or interpretation
of this Agreement. As used in this Agreement, the words “include” and “including” and variations thereof,
will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.”
The headings in this Agreement will not be referred to in connection with the construction or interpretation of this Agreement.
This Agreement is in the English language only, which language shall be controlling in all respects, and all notices under this
Agreement shall be in the English language.

 

6.13 Counterparts. This Agreement may be executed in
counterparts or duplicate originals, both of which shall be regarded as one and the same instrument, and which shall be the official
and governing version in the interpretation of this Agreement. This Agreement may be executed by facsimile signatures or other
electronic means and such signatures shall be deemed to bind each Party as if they were original signatures.

    	17

    	

    

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement
to be signed below by their respective duly authorized officers.

 

Enzo Life Sciences, Inc.

 

	By:	     /s/ Barry M. Weiner	 
	 	 	 
	Name:	     Barry M. Weiner	 
	 	 	 
	Title:	     Vice President	 
	 	 	 
	Date:	     May 13, 2016	 

 

Life Technologies Corporation

 

	By:	     /s/ Seth H. Hoogasian	 
	 	 	 
	Name:	     Seth H. Hoogasian	 
	 	 	 
	Title:	     President	 
	 	 	 
	Date:	     May 13, 2016	 

    	18

    	

    

EXHIBIT A

 

STIPULATED MOTION FOR DISMISSAL OF LITIGATION

 

UNITED STATES DISTRICT COURT

OF DELAWARE

 

	ENZO LIFE SCIENCES, INC.	)	CASE NO. CV 12-CV-105-LPS
	 	)	 
	vs.	)	JOINT STIPULATION OF DISMISSAL WITH PREJUDICE
	 	)	 
	LIFE TECHNOLOGIES CORPORATION	)	The Hon. Leonard Stark
	 	)	Chief United States District Court Judge
	Defendant.	)	 
	 	)	 
	 	)	 

 

Pursuant to Rule 41(a)(1)(A)(ii)
of the Federal Rules of Civil Procedure, Plaintiff, Enzo Life Sciences, Inc. (“Enzo”), and Defendant Life Technologies
Corporation (“Life”), by and through their respective counsel, hereby stipulate to the dismissal with prejudice of
Enzo’s claims against Life in this action and to the dismissal without prejudice of Life’s counterclaims against Enzo.
Each party shall bear its own attorneys’ fees and costs.

 

Respectfully submitted,

 

	FARNAN LLP	 	MORRIS NICHOLS ARSHT &TUNNELL LLP
	 	 	 
	
        Brian E. Farnan (#4089)

        919 North Market Street, 12th Flr

        Wilmington, DE 19801

        (302) 777-0336

        bfarnan@farnanlaw.com
	 	
        Jack B. Blumenfeld (#1014)

        Karen Jacobs (#2881)

        1201 North Market Street

        P.O. Box 1347

        Wilmington, DE 19899

	 	 	(302) 658-9200 
	Of Counsel:	 	jblumenfeld@mnat.com
	 	 	kjacobs@mnat.com
	
        John M. Desmarais (admitted pro hac vice)

        Michael P. Stadnick (admitted pro hac vice)

        Justin P.D. Wilcox (admitted pro hac vice)

        Jordan N. Malz (admitted pro hac vice)

        Peter C. Magic (admitted pro hac vice)
	 	
        

Attorneys for Defendant

        Life Technologies Corporation

    	19

    	

    

Desmarais LLP

230 Park Avenue

New York, NY 10169

(212) 351-3400 (Tel)

(212) 351-3401 (Fax)

jdesmarais@desmaraisllp.com

mstadnick@desmaraisllp.com

jwilcox@desmaraisllp.com

jmalz@desmaraisllp.com

pmagic@desmaraisllp.com

 

Attorneys for Plaintiff

Enzo Life Sciences, Inc.

    	20

    	

    

EXHIBIT B

Enzo’s Infringement Contentions
and Infringement Charts

    	21

    	

    

Exhibit B

 

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

 

	ENZO LIFE SCIENCES, INC.,	 	 
	 	 	 
	Plaintiff,	 	Civil Action No. 12-cv-l05-LPS
	v.	 	 
	 	 	 
	LIFE TECHNOLOGIES CORPORATION,	 	 
	 	 	 
	 	 	 
	Defendant.	 	 
	 	 	 

 

PLAINTIFF’S INITIAL INFRINGEMENT CHARTS

FOR LIFE TECHNOLOGIES CORPORATION

 

Pursuant to the Court’s
Scheduling Order, Plaintiff Enzo Life Sciences, Inc. (“Plaintiff’) hereby provides its Initial Infringement Charts to Defendant
Life Technologies Corporation (“Life Technologies”).

 

Plaintiff contends that
Life Technologies, either alone or in conjunction with others, has directly infringed and continues to directly infringe, one or
more claims of U.S. Patent No. 7,064,197 (“the ‘197 patent”) and U.S. Patent No. 6,992,180 (“the ‘180 patent”)
(collectively, the “Patents-in-Suit”) under 35 U.S.C. § 271, either literally and/or under the doctrine of equivalents,
by making, using, offering to sell, selling, and/or importing into the United States certain nucleic acid probe and array products,
including without limitation:

 

	 	a)	nucleic acid probe products involving TaqMan technology, including without limitation, TaqMan Gene Expression assays, TaqMan SNP Genotyping assays, TaqMan Drug Metabolism Genotyping Assays, TaqMan Copy Number Variation assays, TaqMan Mutation Detection Assays, TaqMan MicroRNA assays, TaqMan

    	1

    	

    

Exhibit B

 

	 	 	siRNA assays, TaqMan Non-coding RNA assays, TaqMan Protein assays,
    Custom TaqMan Probes, and Custom TaqMan assays, including Custom TaqMan Gene Expression assays, Custom TaqMan SNP Genotyping Assays, and Custom and Custom Plus TaqMan Copy Number assays, and Custom TaqMan Small RNA assays (collectively, “TaqMan Assays”);
	 	 	 
	 	b)	nucleic acid array products involving Dynabeads technology, including without limitation,
    Dynabeads Oligo (dT)25 (all sizes), Dynabeads mRNA DIRECT kits, and Dynabeads mRNA Purification kits (collectively,
    “Dynabeads Oligo (dT)25 Products”);
	 	 	 
	 	c)	the NCode Human miRNA Microarray V3; and 
	 	 	 
	 	d)	nucleic acid array products products involving the NCode platform for non-coding RNA, including without limitation, NCode Non-coding RNA assay, NCode Human Non-coding RNA Microarrays, and NCode Mouse Non-coding RNA Microarrays (collectively, “NCode Noncoding RNA Products”)

 

(collectively, the “Accused Products”).
Plaintiff further contends that Life Technologies has actively induced, and continues to induce, the infringement of one or
more claims of the Patents-in-Suit under 35 U.S.C. § 271 (b). At all relevant times, Life Technologies has actively,
knowingly, and intentionally induced others, including without limitation Life Technologies’ customers to use, make,
sell, offer for sale, and/or import the Accused Products, in a way that Life Technologies knew or should have known infringes
one or more claims of the Patents-in-Suit. Plaintiff further contends that Life Technologies’ infringement of the
‘180 patent has been, and continues to be, willful.

    	2

    	

    

Exhibit B

 

Plaintiffs initial infringement contentions are
provided herein without the benefit of full discovery. The initial claim charts attached herein as Exhibits A-I through B-3 identify
where each limitation of the asserted claims of the Patents-in-Suit is found within the Accused Products. Plaintiff contends that
each element of each asserted claim is literally present in the Accused Products unless otherwise indicated. But to the extent
that any claim element is found not to be literally embodied in the accused instrumentalities, Plaintiff contends that the Accused
Products embody such claim elements under the doctrine of equivalents because there are no substantial differences for each claim
element, and the Accused Products perform substantially the same function, in substantially the same way, to achieve substantially
the same result. To date, Life Technologies has not provided non-infringement contentions in this case. Plaintiff reserves the
right to supplement its initial infringement contentions, including doctrine of equivalents contentions, in response to Life Technologies’
non-infringement contentions.

 

Where a claim element is implemented in the
same or substantially the same way for each product of an Accused Product family (e.g. , Dynabeads Oligo (dT)25
Products include Dynabeads Oligo (dT)25 (all sizes), Dynabeads mRNA DIRECT kits, and Dynabeads mRNA Purification kits),
Plaintiff provides an exemplary illustration or description setting forth specifically where the limitation is found in the Accused
Products, without repeating the same illustration or description for each version of each Accused Product in the family.

 

Plaintiff provides these initial infringement
contentions before claim construction disclosures and fulsome discovery, and before the Court’s claim construction ruling. Plaintiffs
initial infringement contentions are not an admission, adoption, or waiver of any particular claim construction; Plaintiff reserves
all rights with respect to claim construction.

    	3

    	

    

Exhibit B

 

These initial infringement charts are based
upon information reasonably and presently available to Plaintiff through publicly-available information and
Life Technologies’ production of core technical documents to date. Plaintiff reserves the right, consistent with its
obligations under the Federal Rules of Civil Procedure, the Local Rules, the Court’s Scheduling Order, and the Default
Standard for Discovery, including Discovery of Electronically Stored Information, to modify, amend, retract, and/or
supplement the initial infringement charts made herein as additional evidence and information becomes available or as
otherwise appropriate, including the issuance of the Court’s claim construction ruling.

 

Plaintiff identifies the following asserted
claims of the Patents-in-Suit and accused instrumentalities, as further explained in Exhibits A-I through B-3 .

 

	Patent-In-

Suit	 	Asserted Claims	 	Life Technologies – Accused
    

Products 
	 	 	 	 	 
	6,992,180	 	1, 2, 6, 7, 8, 9, 12, 13, 14, 15, 19, 25, 29, 30, 34,     35,
    36,     40, 41, 42, 43, 44, 48, 54, 58, 59, 60, 64, 65, 66, 70, 71, 72, 73, 77, 83, 87, 88, 92, 93, 94, 98, 99, 100, 101,
    102,     106, 112,     116	 	TaqMan® Assays. See Ex. A-1.
	 	 	 	 	 
	7,064,197	 	17,
    19, 105, 113, 116, 129, 131	 	Dynabeads®Oligo (dT)25 Products. See Ex.
    B-1.
	 	 	 	 	 
	7,064,197	 	1-22, 27-34, 38-40, 43, 46, 47, 49, 51, 57, 59,     61-63, 65,
    68-70, 72-74, 78, 80, 81, 84-88, 90, 96, 98, 102, 105, 106, 108, 113, 115, 116, 118, 121, 122, 124, 127-129, 131, 132, 136,
    140,     146,     148, 192-194, 197, 199, 204, 206, 212, 213, 218, 220-222, 224, 226, 227, 230, 232, 235	 	NCodeTM Human miRNA Microarray V3. See Ex. B-2.
	 	 	 	 	 
	7,064,197	 	1-22, 27-34, 38, 39, 40, 43, 44, 46, 47, 49, 51,     57, 59,
    61-63, 65, 68-70, 72, 73, 74, 78, 80-82, 84-88, 90, 96, 98, 100, 102, 105, 106, 108, 113,     115, 116, 118, 120, 122, 123,
    124,     127-129, 131, 132, 136, 140, 146, 148, 191-194, 196, 197, 199, 204, 206, 212, 213, 218, 220-222, 224, 226, 227,
    230, 232, 234	 	NCodeTM Noncoding RNA Products. See Ex. B-3.

 

DATED: September 30, 2013

    	4

    	

    

Exhibit B

 

	 	/s/ Brian E. Farnan
	 	Brian E. Farnan (Bar No. 4089)
	 	Farnan LLP
	 	919 North Market Street
	 	12th Floor
	 	Wilmington, DE 19801
	 	(302) 777-0300
	 	(302) 777-0301
	 	bfarnan@farnanlaw.com
	 	 
	 	John M. Desmarais
	 	Michael P. Stadnick
	 	Xiao Li
	 	Joseph C. Akalski
	 	Lauren M. Nowierski
	 	Desmarais
    LLP
	 	230 Park Avenue
	 	New York, NY 10169
	 	(212) 351-3400 (Tel)
	 	(212) 351-3401 (Fax)
	 	jdesmarais@desmaraisllp.com
	 	mstadnick@desmaraisllp.com
	 	xli@desmaraisllp.com
	 	jakalski@desmaraisllp.com
	 	lnowierski@desmaraisllp.com
	 	 
	 	Counsel for Plaintiff

    	5

    	

    

Exhibit B

 

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

 

	ENZO LIFE SCIENCES, INC.,	 	 
	 	 	 
	Plaintiff,	 	Civil Action No. 12-cv-105-LPS
	 	 	 
	v.	 	 
	 	 	 
	LIFE TECHNOLOGIES CORPORATION,	 	 
	 	 	 
	Defendant.	 	 
	 	 	 

 

PLAINTIFF’S SUPPLEMENTAL INFRINGEMENT CHARTS

 FOR LIFE
TECHNOLOGIES CORPORATION

 

Pursuant to the Court’s Scheduling Order,
Plaintiff Enzo Life Sciences, Inc. (“Plaintiff”) hereby provides its Supplemental Infringement Charts to Defendant Life
Technologies Corporation (“Life Technologies”).

 

Plaintiff contends that Life Technologies, either
alone or in conjunction with others, has directly infringed and continues to directly infringe, one or more claims of U.S. Patent
No. 7,064,197 (“the ‘197 patent”) and U.S. Patent No. 6,992,180 (“the ‘180 patent”) (collectively,
the “Patents-in-Suit”) under 35 U.S.C. § 271, either literally and/or under the doctrine of equivalents, by making,
using, offering to sell, selling, and/or importing into the United States certain nucleic acid probe and array products, including
without limitation:

 

		a)	nucleic acid probe products involving TaqMan technology, including without limitation, TaqMan
Gene Expression assays, TaqMan SNP Genotyping assays, TaqMan Drug Metabolism Genotyping Assays, TaqMan Copy Number Variation assays,
TaqMan Mutation Detection Assays, TaqMan MicroRNA assays, TaqMan

    	1

    	

    

Exhibit B

 

	 	 	siRNA assays, TaqMan Non-coding RNA assays, TaqMan Protein assays, Custom TaqMan Probes, and Custom TaqMan assays, including Custom TaqMan Gene Expression assays, Custom TaqMan SNP Genotyping Assays, and Custom and Custom Plus TaqMan Copy Number assays, and Custom TaqMan Small RNA assays (collectively, “TaqMan Assays”);

 

	 	b)	nucleic acid array products involving Dynabeads technology, including
    without limitation, Dynabeads Oligo (dT)25 (all sizes), Dynabeads mRNA DIRECT kits, and Dynabeads mRNA Purification
    kits (collectively, “Dynabeads Oligo (dT)25 Products”);

 

	 	c)	nucleic acid array products involving Ion Torrent sequencing technology, including without limitation, Ion 316 Chip Kit (all sizes), Ion PI Chip Kit v2, Ion 314 Chip Kit v2, Ion 318 Chip Kit v2 (all sizes), and Ion 316 Chip Kit v2 (all sizes) (collectively, “Ion Torrent Products”); 
	 	 	 
	 	d)	nucleic acid array products involving SOLiD sequencing chemistry, including without limitation, SOLiD 6-Lane FlowChip (collectively, “SOLiD Sequencing Products”); 
	 	 	 
	 	e)	nucleic acid array products involving Wildfire sequencing technology, including without limitation, 5500 W FlowChip V2 (collectively, “Wildfire Sequencing Products”); 
	 	 	 
	 	f)	the NCode Human miRNA Microarray V3 and NCode Multi-Species miRNA Microarray Kit V2; and 
	 	 	 
	 	g)	nucleic acid array products products involving the NCode platform for non-coding RNA, including without limitation, NCode Non-coding RNA assay,

    	2

    	

    

Exhibit B

 

	 		NCode Human Non-coding RNA Microarrays, and NCode Mouse Non-coding RNA Microarrays
                                                                                  (collectively, “NCode Noncoding RNA Products”)

 

(collectively, the “Accused Products”). Plaintiff further
contends that Life Technologies has actively induced, and continues to induce, the infringement of one or more claims of the Patents-in-Suit
under 35 U.S.C. § 271(b). At all relevant times, Life Technologies has actively, knowingly, and intentionally induced others,
including without limitation Life Technologies’ customers to use, make, sell, offer for sale, and/or import the Accused Products,
in a way that Life Technologies knew or should have known infringes one or more claims of the Patents-in-Suit. Plaintiff further
contends that Life Technologies’ infringement of the ‘180 patent has been, and continues to be, willful.

 

Plaintiff’s infringement contentions are
provided herein without the benefit of full discovery. The claim charts attached herein as Exhibits A-1 through B-6 identify where
each limitation of the asserted claims of the Patents-in-Suit is found within the Accused Products. Plaintiff contends that each
element of each asserted claim is literally present in the Accused Products unless otherwise indicated. But to the extent that
any claim element is found not to be literally embodied in the accused instrumentalities, Plaintiff contends that the Accused Products
embody such claim elements under the doctrine of equivalents because there are no substantial differences for each claim element,
and the Accused Products perform substantially the same function, in substantially the same way, to achieve substantially the same
result. To date, Life Technologies has not provided non-infringement contentions in this case. Plaintiff reserves the right to
supplement its infringement contentions, including doctrine of equivalents contentions, in response to Life Technologies’
non-infringement contentions.

    	3

    	

    

Exhibit B

 

Where a claim element is implemented in the
same or substantially the same way for each product of an Accused Product family (e.g., Dynabeads Oligo (dT)25
Products include Dynabeads Oligo (dT)25 (all sizes), Dynabeads mRNA DIRECT kits, and Dynabeads mRNA Purification kits),
Plaintiff provides an exemplary illustration or description setting forth specifically where the limitation is found in the Accused
Products, without repeating the same illustration or description for each version of each Accused Product in the family.

 

Plaintiff provides these infringement contentions
before fulsome discovery and before the Court’s claim construction ruling. Plaintiff’s infringement contentions are
not an admission, adoption, or waiver of any particular claim construction; Plaintiff reserves all rights with respect to claim
construction.

 

These infringement charts are based upon information
reasonably and presently available to Plaintiff through publicly-available information and Life Technologies’ production
of core technical documents to date. Plaintiff reserves the right, consistent with its obligations under the Federal Rules of Civil
Procedure, the Local Rules, the Court’s Scheduling Order, and the Default Standard for Discovery, including Discovery of
Electronically Stored Information, to modify, amend, retract, and/or supplement the infringement charts made herein as additional
evidence and information becomes available or as otherwise appropriate, including the issuance of the Court’s claim construction
ruling.

 

Plaintiff identifies the following asserted claims
of the Patents-in-Suit and accused instrumentalities, as further explained in Exhibits A-1 through B-6.

 

	Patent-In- 

Suit	 	Asserted Claims	 	Life Technologies – Accused 

Products
	 	 	 	 	 
	6,992,180	 	1, 2, 6, 7, 8, 9, 12, 13, 14, 15, 19, 25, 29, 30, 34, 35,
    36, 40, 41, 42, 43, 44, 48, 54, 58, 59, 60, 64, 65, 66, 70, 71, 72, 73, 77, 83, 87, 88, 92, 93, 94, 98, 99, 100, 101, 102, 106, 112, 116	 	TaqMan® Assays. See Ex. A-1.

 

 

    	4

    	

    

Exhibit B

 

	Patent-In- 

    Suit	 	Asserted
    Claims	 	Life
    Technologies – Accused 

    Products
	 	 	 	 	 
	7,064,197	 	17, 19, 105,
    113, 116, 129, 131	 	Dynabeads®Oligo
    (dT)25 Products.
    See Ex. B-1.
	 	 	 	 	 
	7,064,197	 	1-22, 27-34,
    38-40, 43, 46, 47, 49, 51, 57, 59, 61-63, 65, 68-70, 72-74, 78, 80, 81, 84-88, 90, 96, 98, 102, 105, 106, 108, 113, 115, 116,
    118, 121, 122, 124, 127-129, 131, 132, 136, 140, 146, 148, 192-194, 197, 199, 204, 206, 212, 213, 218, 220-222, 224, 226,
    227, 230, 232, 235	 	NCodeTM
    Human miRNA Microarray V3 and Multi-Species miRNA Microarray V2. See Ex. B-2
    (Amended).
	 	 	 	 	 
	7,064,197	 	1-22, 27-34,
    38, 39, 40, 43, 44, 46, 47, 49, 51, 57, 59, 61-63, 65, 68-70, 72, 73, 74, 78, 80-82, 84-88, 90, 96, 98, 100, 102, 105, 106,
    108, 113, 115, 116, 118, 120, 122, 123, 124, 127-129, 131, 132, 136, 140, 146, 148, 191-194, 196, 197, 199, 204, 206, 212,
    213, 218, 220-222, 224, 226, 227, 230, 232, 234	 	NCodeTM
    Noncoding RNA Products. See Ex. B-3.
	 	 	 	 	 
	7,064,197	 	17, 19, 106,
    113, 116-119, 128, 129	 	Ion
    Torrent Products. See Ex. B-4.
	 	 	 	 	 
	7,064,197	 	3, 5, 10, 11,
    17-22, 29, 30, 32, 33, 38-40, 43, 44, 46, 47, 51, 59, 65, 72, 73, 78, 80-82, 84-86, 90, 98, 105, 106, 108, 113, 115, 116,
    118, 122-124, 128, 129, 131, 132, 136, 140, 148, 226, 227, 232	 	SOLiD
    Sequencing Products. See Ex. B-5.
	 	 	 	 	 
	7,064,197	 	3, 5, 10, 11,
    17-23, 25, 26, 29, 30, 32, 33, 38-41, 43, 44, 46, 47, 51, 59, 65, 72, 73, 78, 80, 81, 82, 84-86, 90, 98, 105, 106, 113, 115-119,
    122-124, 128, 129, 132, 136, 140, 148, 150-153, 155-157, 161, 168, 176, 178, 185, 187, 188, 226, 227, 231-233	 	Wildfire
    Sequencing Products. See Ex. B-6.

 

	DATED:   February 5, 2014	Respectfully submitted,
	 	 	 
	 	 	FARNAN llp
	 	 	 
	 	 	/s/ Brian E. Farnan
	 	 	Brian E. Farnan (Bar No. 4089)
	 	 	Michael J. Farnan (Bar No. 5165)
	 	 	919 North Market Street
	 	 	12th Floor
	 	 	Wilmington, DE 19801
	 	 	(302) 777-0300 (Tel)
	 	 	(302) 777-0301 (Fax)

    	5

    	

    

Exhibit B

 

	 	bfarnan@farnanlaw.com
	 	mfarnan@farnanlaw.com
	 	 
	 	John M. Desmarais (admitted pro hac vice)
	 	Michael P. Stadnick (admitted pro hac vice)
	 	Xiao Li (admitted pro hac vice)
	 	Joseph C. Akalski (admitted pro hac vice)
	 	Lauren M. Nowierski (admitted pro hac vice)
	 	DESMARAIS llp
	 	230 Park Avenue
	 	New York, NY 10169
	 	(212) 351-3400 (Tel)
	 	(212) 351-3401 (Fax)
	 	jdesmarais@desmaraisllp.com
	 	mstadnick@desmaraisllp.com
	 	xli@desmaraisllp.com
	 	jakalski@desmaraisllp.com
	 	lnowierski@desmaraisllp.com
	 	 
	 	Counsel for Plaintiff

    	6

    	

    

Exhibit B

 

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

 

	ENZO LIFE SCIENCES, INC.,	 	 
	 	 	 
	Plaintiff,	 	Civil Action No. 12-cv-105-LPS
	 	 	 
	v.	 	 
	 	 	 
	LIFE
    TECHNOLOGIES CORPORATION,	 	 
	 	 	 
	Defendant.	 	 
	 	 	 

 

PLAINTIFF’S SECOND SUPPLEMENTAL INFRINGEMENT
CHARTS

 FOR LIFE TECHNOLOGIES

 

Pursuant to the Court’s
Scheduling Order, Plaintiff Enzo Life Sciences, Inc. (“Plaintiff”) hereby provides its Second Supplemental Infringement
Charts to Defendant Life Technologies Corporation (“Life Technologies”).

 

Plaintiff contends that Life Technologies, either
alone or in conjunction with others, has directly infringed and continues to directly infringe, one or more claims of U.S. Patent
No. 7,064,197 (“the ‘197 patent”) and U.S. Patent No. 6,992,180 (“the ‘180 patent”) (collectively,
the “Patents-in-Suit”) under 35 U.S.C. § 271, either literally and/or under the doctrine of equivalents, by making,
using, offering to sell, selling, and/or importing into the United States certain nucleic acid probe and array products, including
without limitation:

 

		a)	nucleic acid probe products involving TaqMan technology, including without limitation, TaqMan
Gene Expression assays, TaqMan SNP Genotyping assays, TaqMan Drug Metabolism Genotyping Assays, TaqMan Copy Number Variation assays,
TaqMan Mutation Detection Assays, TaqMan MicroRNA assays, TaqMan

    	1

    	

    

Exhibit B

 

	 	 	siRNA assays, TaqMan Non-coding RNA assays, TaqMan Protein assays, Custom TaqMan Probes, and Custom TaqMan assays, including Custom TaqMan Gene Expression assays, Custom TaqMan SNP Genotyping Assays, and Custom and Custom Plus TaqMan Copy Number assays, and Custom TaqMan Small RNA assays, and all other nucleic acid probe products involving TaqMan technology (collectively, “TaqMan Assays”);

 

	 	b)	nucleic acid array products involving Dynabeads technology, including without limitation, Dynabeads Oligo (dT)25 (all sizes), Dynabeads mRNA DIRECT kits, Dynabeads mRNA Purification kits, Dynabeads® mRNA DIRECTTM Micro Purification Kit, Dynabeads M-280 Streptavidin, Dynabeads MyOne Streptavidin T1, Dynabeads M-270 Streptavidin, Dynabeads MyOne Streptavidin C1, Dynabeads kilobaseBINDER Kit, CELLection Biotin Binder Kit, Dynabeads® MyOneTM Silane, Dynabeads® DNA DIRECTTM Blood Kit, Dynabeads® DNA DIRECTTM Universal Kit, Dynabeads® SILANE Genomic DNA Kit, Dynabeads® SILANE Viral NA Kit, Dynabeads® SILANE Genomic DNA Kit, Dynabeads® Streptavidin Trial Kit, and Custom-coupled Dynabeads, and all other nucleic acid array products involving Dynabeads technology (collectively, “Dynabeads Products”);

 

	 	c)	nucleic acid array products involving Ion Torrent sequencing technology, including without limitation, products containing Ion Sphere Particles (including, without limitation, Ion Sequencing Kits (all versions), Ion Template Kits (all versions), Ion Xpress Template Kits (all versions), Ion OneTouch Template Kits (all versions)), Ion Proton I Chip (all versions), Ion Proton II Chip (all versions),

    	2

    	

    

Exhibit B

 

	 	 	Ion 316 Chip Kits (all versions and sizes), Ion PI Chip Kits (all versions and sizes), Ion 314 Chip Kits (all versions and sizes), Ion 318 Chip Kits (all versions and sizes), and Ion 316 Chip Kits (all versions and sizes), and all other nucleic acid array products involving Ion Torrent sequencing technology(collectively, “Ion Torrent Products”);

 

	 	d)	nucleic acid array products involving SOLiD sequencing chemistry, including without limitation, products containing SOLiD sequencing beads and SOLiD 6-Lane FlowChip, and all other nucleic acid array products involving SOLiD sequencing chemistry (collectively, “SOLiD Sequencing Products”);
	 	 	 
	 	e)	nucleic acid array products involving Wildfire sequencing technology, including without limitation, 5500 W FlowChip V2, and all other nucleic acid array products involving Wildfire sequencing technology (collectively, “Wildfire Sequencing Products”);
	 	 	 
	 	f)	the NCode Human miRNA Microarray V3, NCode Multi-Species miRNA Microarray Kit V2, and NCodeTM Multi-Species miRNA Pre-printed Microarrays, and all other products involving the NCode platform for miRNA (collectively, “NCode miRNA Microarray Products”); and
	 	 	 
	 	g)	nucleic acid array products involving the NCode platform for non-coding RNA, including without limitation, NCode Non-coding RNA assay, NCode Human Non-coding RNA Microarrays, and NCode Mouse Non-coding RNA Microarrays, and all other nucleic acid array products involving the Ncode platform for non-coding RNA (collectively, “NCode Noncoding RNA Products”)

    	3

    	

    

Exhibit B

 

(collectively, the “Accused Products”). Plaintiff further
contends that Life Technologies has actively induced, and continues to induce, the infringement of one or more claims of the Patents-in-Suit
under 35 U.S.C. § 271(b). At all relevant times, Life Technologies has actively, knowingly, and intentionally induced others,
including without limitation Life Technologies’ customers to use, make, sell, offer for sale, and/or import the Accused Products,
in a way that Life Technologies knew or should have known infringes one or more claims of the Patents-in-Suit. Plaintiff further
contends that Life Technologies’ infringement of the ‘180 patent has been, and continues to be, willful.

 

Plaintiff’s infringement contentions are
provided herein without the benefit of full discovery. The claim charts attached herein as Exhibits A-1 through B-6 identify where
each limitation of the asserted claims of the Patents-in-Suit is found within the Accused Products. Plaintiff contends that each
element of each asserted claim is literally present in the Accused Products unless otherwise indicated. But to the extent that
any claim element is found not to be literally embodied in the accused instrumentalities, Plaintiff contends that the Accused Products
embody such claim elements under the doctrine of equivalents because there are no substantial differences for each claim element,
and the Accused Products perform substantially the same function, in substantially the same way, to achieve substantially the same
result. To date, Life Technologies has not provided non-infringement contentions in this case. Plaintiff reserves the right to
supplement its infringement contentions, including doctrine of equivalents contentions, in response to Life Technologies’
non-infringement contentions.

 

Where a claim element is implemented in the same
or substantially the same way for each product of an Accused Product family (e.g., Dynabeads Oligo (dT)25 Products
include Dynabeads Oligo (dT)25 (all sizes), Dynabeads mRNA DIRECT kits, Dynabeads mRNA

    	4

    	

    

Exhibit B

 

Purification kits, Dynabeads M-280 Streptavidin, Dynabeads MyOne
Streptavidin T1, Dynabeads M-270 Streptavidin, Dynabeads MyOne Streptavidin C1, Dynabeads kilobaseBINDER Kit, CELLection Biotin
Binder Kit, and Custom-coupled Dynabeads), Plaintiff provides an exemplary illustration or description setting forth specifically
where the limitation is found in the Accused Products, without repeating the same illustration or description for each version
of each Accused Product in the family.

 

Plaintiff provides these infringement contentions
before fulsome discovery and before the Court’s claim construction ruling. Moreover, depositions are ongoing, and Plaintiff
reserves the right to supplement its contentions based on additional relevant information disclosed during depositions and through
other means of discovery. And to the extent that Plaintiff receives relevant discovery from third parties, Plaintiff reserves the
right to supplement its contentions accordingly. Plaintiff’s infringement contentions are not an admission, adoption, or
waiver of any particular claim construction; Plaintiff reserves all rights with respect to claim construction.

 

These infringement charts are based upon information
reasonably and presently available to Plaintiff through publicly-available information and Life Technologies’ production
of technical documents to date. Plaintiff reserves the right, consistent with its obligations under the Federal Rules of Civil
Procedure, the Local Rules, the Court’s Scheduling Order, and the Default Standard for Discovery, including Discovery of
Electronically Stored Information, to modify, amend, retract, and/or supplement the infringement charts made herein as additional
evidence and information becomes available or as otherwise appropriate, including the issuance of the Court’s claim construction
ruling.

 

Plaintiff identifies the following asserted claims
of the Patents-in-Suit and accused instrumentalities, as further explained in Exhibits A-1 through B-6.

    	5

    	

    

Exhibit B

 

	Patent-In- 

Suit	 	Asserted Claims	 	Life Technologies – Accused 

Products
	 	 	 	 	 
	6,992,180	 	1, 2, 6, 7, 8, 9, 12, 13, 14, 15, 19, 25, 29, 30, 34, 35, 36, 40, 41, 42, 43, 44, 48, 54, 58, 59, 60, 64, 65, 66, 70, 71, 72, 73, 77, 83, 87, 88, 92, 93, 94, 98, 99, 100, 101, 102, 106, 112, 116	 	TaqMan® Assays. See
Ex. A-1.
	 	 	 	 	 
	7,064,197	 	17, 19, 105, 113, 116, 129, 131	 	Dynabeads® Products. See Ex. B-1.
	 	 	 	 	 
	7,064,197	 	1-22, 27-34, 38-40, 43, 46, 47, 49, 51, 57, 59, 61-63, 65, 68-70, 72-74, 78, 80, 81, 84-88, 90, 96, 98, 102, 105, 106, 108, 113, 115, 116, 118, 121, 122, 124, 127-129, 131, 132, 136, 140, 146, 148, 192-194, 197, 199, 204, 206, 212, 213, 218, 220-222, 224, 226, 227, 230, 232, 235	 	NCodeTM miRNA Microarray Products. See Ex. B-2 (Amended).
	 	 	 	 	 
	7,064,197	 	1-22, 27-34, 38, 39, 40, 43, 44, 46, 47, 49, 51, 57, 59, 61-63, 65, 68-70, 72, 73, 74, 78, 80-82, 84-88, 90, 96, 98, 100, 102, 105, 106, 108, 113, 115, 116, 118, 120, 122, 123, 124, 127-129, 131, 132, 136, 140, 146, 148, 191-194, 196, 197, 199, 204, 206, 212, 213, 218, 220-222, 224, 226, 227, 230, 232, 234	 	NCodeTM Noncoding RNA Products. See Ex. B-3.
	 	 	 	 	 
	7,064,197	 	17, 19, 106, 113, 116-119, 128, 129	 	Ion Torrent Products. See Ex. B-4.
	 	 	 	 	 
	7,064,197	 	3, 5, 10, 11, 17-22, 29, 30, 32, 33, 38-40, 43, 44, 46, 47, 51, 59, 65, 72, 73, 78, 80-82, 84-86, 90, 98, 105, 106, 108, 113, 115, 116, 118, 122-124, 128, 129, 131, 132, 136, 140, 148, 226, 227, 232	 	SOLiD Sequencing Products. See Ex. B-5.
	 	 	 	 	 
	7,064,197	 	3, 5, 10, 11, 17-23, 25, 26, 29, 30, 32, 33, 38-41, 43, 44, 46, 47, 51, 59, 65, 72, 73, 78, 80, 81, 82, 84-86, 90, 98, 105, 106, 113, 115-119, 122-124, 128, 129, 132, 136, 140, 148, 150-153, 155-157, 161, 168, 176, 178, 185, 187, 188, 226, 227, 231-233	 	Wildfire Sequencing Products. See Ex. B-6.

 

DATED: September 30, 2014

 

	 	/s/ Brian E. Farnan
	 	Brian E. Farnan (Bar No. 4089)
	 	Farnan LLP
	 	919 North Market Street
	 	12th Floor
	 	Wilmington, DE 19801

    	6

    	

    

Exhibit B

 

	 	(302) 777-0300
	 	(302) 777-0301
	 	bfarnan@farnanlaw.com
	 	 
	 	John M. Desmarais (admitted pro hac vice) 
	 	Michael P. Stadnick (admitted pro hac vice) 
	 	Jordan N. Malz (admitted pro hac vice) 
	 	Justin P.D. Wilcox (admitted pro hac vice) 
	 	Peter C. Magic (admitted pro hac vice) 
	 	Joseph C. Akalski (admitted pro hac vice) 
	 	Jessica A. Martinez (admitted pro hac vice) 
	 	Danielle A. Shultz (admitted pro hac vice)
	 	Desmarais LLP
	 	230 Park Avenue 
	 	New York, NY 10169 
	 	(212) 351-3400 
	 	(212) 351-3401 
	 	jdesmarais@desmaraisllp.com 
	 	mstadnick@desmaraisllp.com 
	 	jmalz@desmaraisllp.com 
	 	jwilcox@desmaraisllp.com 
	 	pmagic@desmaraisllp.com 
	 	jakalski@desmaraisllp.com 
	 	jmartinez@desmaraisllp.com 
	 	dshultz@desmaraisllp.com
	 	Counsel for Plaintiff

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]